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Abstract 
Soft tissues, such as rotator cuff tendons and the anterior cruciate ligament 
(ACL), integrate with the subchondral bone through a complex multi-tissue 
interface that functions to minimize the formation of stress concentrations and 
enable the efficient transfer of load between tendon or ligament and bone. 
Current rotator cuff tendon and ACL repair techniques, requiring the 
reattachment of the tendon/ligament to its original bony footprint, fail to 
regenerate this interface. Instead, the repaired insertion site transitions from 
tendon/ligament to bone through a disorganized, fibrovascular scar tissue with 
weak mechanical properties, leaving it prone to failure and compromising long-
term clinical outcomes. To improve tendon-bone integration following rotator cuff 
repairs, the objective of this thesis was to utilize a scaffold-less tissue engineered 
construct to promote the regeneration of the tendon-bone interface and develop 
a reproducible, automated manufacturing system to facilitate the advancement of 
the construct towards clinical use. Matrix organization and mechanical properties 
of the regenerated enthesis were evaluated in both acute (immediate repair) and 
chronic (repair 4 weeks post injury) supraspinatus tear rat models. Utilization of 
tissue-engineered constructs resulted in superior enthesis regeneration 
compared to current mechanical fixation techniques.  
 
Next, to enhance the reproducibility and uniformity of existing multi-phasic 
scaffold-less construct fabrication methodologies, protocol standards and a novel 
delamination system were developed and later extrapolated for use with human 
derived constructs. The novel construct fabrication methods yielded an increased 
number of engineered constructs of consistent size and mechanical properties. 
Temporal gene expression confirmed the commitment of human derived 
constructs toward tendon and bone-like tissues. Lastly, to facilitate the eventual 
 xvi 
large-scale commercial production of our multiphasic tissues, a novel semi-
closed bioreactor system was developed and validated. The use of the bioreactor 
successfully facilitated the co-culture and integration of two distinct tissue types 
in a single chamber without any direct user manipulation. The findings described 
in this thesis will lead to the development of a new soft-tissue-to-bone repair 
strategy to improve functional tendon/ligament repair outcomes and provide the 
framework for expediting the clinical and commercial translation of our tissue 
engineering technologies. 
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Chapter 1  
Introduction 
1.1 Specific Aims 
Rotator cuff injuries are one of the most common orthopedic disorders affecting 
the shoulder with approximately 75,000 repair procedures performed each year 
in the United States 169. Rotator cuff tears typically involve the supraspinatus 
tendon at the tendon-bone insertion (enthesis) and are often the cause of 
significant pain and weakness. Due to the complex anatomy of the shoulder, 
degenerative changes within the joint and relative hypo-vascularity of the tendon, 
large tears (>3 cm) do not heal on their own and often require surgical 
intervention to improve symptomatic injuries. Current primary repair techniques 
utilize suture to reattach and securely fix the ruptured tendon to its bony 
insertion. Failure rates, however, with these techniques are unacceptably high 
(20-94%) and are likely due, at least in part, to the inability to regenerate the 
native tissue properties of the enthesis during repair.  Healing at the enthesis, 
with current fixation methods, forms a notably weaker, less-organized 
fibrovascular tissue rather than a mechanically and compositionally graded tissue 
interface. The organized heterogeneity of the enthesis serves to minimize strain 
concentrations at this interface and enables load transfer between the soft tissue 
and bone. Failure to promote native enthesis regeneration can leave the repair 
site prone to failure and compromise long-term clinical outcomes. As such, there 
is a need for tissue engineering strategies to recapitulate the enthesis to improve 
functional outcomes following repair. 
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Our lab has established a scaffold-less method for engineering 3D tissue 
constructs derived from mesenchymal stem cells (MSCs). In vitro, MSCs are 
differentiated towards tendon/ligament and bone pathways to form early stage 
and initially extensible constructs that rapidly remodel in vivo to form mature, 
functional replacement tissues. The combination of these two distinct tissue 
types in co-culture forms a bi-phasic construct that when used in a sheep ACL 
repair model quickly integrates with the host tissue and re-establishes a 
functional enthesis 105. The success of our constructs to regenerate the 
tendon/ligament-bone interface of the ACL prompted the investigation of our 
tissue in a rotator cuff repair model to enhance regeneration of the native tendon 
insertion site thereby improving repair outcomes. 
 
Additionally, for effective translation of this technology for clinical use, well-
characterized and reproducible manufacturing processes must be established 
that are suited for large-scale commercial production and are compliant with 
current FDA regulations. Following the development of suitable methodologies, 
incorporation of these practices into a closed and automated bioreactor system 
can provide a means to generate efficient, reproducible, and safe constructs in a 
cost-effective way. The consideration and transition of current laboratory 
methodologies towards translational manufacturing strategies early in the 
developmental process can significantly lessen the technical, regulatory, and 
commercial hurdles plaguing the field of tissue engineering and regenerative 
medicine. 
 
As such, the goal of this thesis was to design and utilize our scaffold-less 
constructs to improve enthesis regeneration following rotator cuff repair and to 
develop a standardized process and manufacturing system for closed, 
commercially relevant, construct production. To achieve this goal, I have 
completed the following aims: 
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Aim 1:  Evaluate the efficacy of scaffold-less constructs to regenerate the 
enthesis following acute and chronic rotator cuff repair. 
  
Aim 2:  Develop standardized and clinically relevant methodologies for 
uniform and reproducible construct fabrication. 
 
Aim 3:  Design, build, and evaluate a commercially relevant bioreactor 
system for closed, automated bone-ligament-bone (BLB) construct 
fabrication. 
  
The purpose of this thesis is to significantly advance the commercialization of this 
technology and hopefully hasten its clinical availability for the treatment of 
musculoskeletal injuries involving the ACL and rotator cuff tendons. 
 
1.2 Rotator Cuff Injury, Repair, and Existing Limitations 
1.2.1 Rotator Cuff Injury 
The rotator cuff functions to stabilize the glenohumeral joint and control shoulder 
movement.  The rotator cuff is comprised of four muscles and associated 
tendons that include the supraspinatus, infraspinatus, teres minor and 
subscapularis (Figure 1.1A). Rotator cuff tendon tears are one of the most 
common injuries affecting the shoulder, with over 75,000 repair procedures 
performed annually in the United States 169. Rotator cuff tears most commonly 
involve partial thickness or full thickness rupture of the supraspinatus tendon 
near the tendon-to-bone interface of the humeral head 78 (Figure 1.1B). 
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Figure 1.1 Rotator Cuff Anatomy A) Native shoulder, and B) Full-thickness supraspinatus 
tendon tear. (http://www.smith-nephew.com/patient/health-concerns/sports-
injuries/shoulder-injuries/rotator-cuff-tear/) 
 
The two main mechanisms of rotator cuff injury are acute and chronic tears. 
Acute tears account for less than 10% of all rotator cuff tears and arise as a 
result of sudden high-impact motions, or are usually sustained following a fall or 
shoulder dislocation 12. Most rotator cuff tears (~90%) are chronic in nature and 
occur as the result of repetitive wear over time 161. Patient age has been 
implicated as a key contributing factor for the increased frequency and size of 
chronic rotator cuff tears in the elderly population 20,75,144,161. A cadaveric study 
showed that 30% of people over age 60 displayed signs of degenerative tears 
compared to only 6% of those younger than 60 90. 
 
Rotator cuff injuries typically involve one or more tendon tears leading to a loss of 
function, instability, pain, and compromised joint mechanics 78. Due to the hypo-
vascularization and degenerative weakening of the tendon with age, as well as, 
the complex anatomy and extensive range of motion associated with the 
shoulder joint, tears of the rotator cuff tendons do not heal 58,60,108,143,144,182. 
Treatment of rotator cuff injuries can be managed conservatively with anti-
inflammatory medication, steroid injections, and physical therapy aimed to 
reduce pain and restore strength 23. However, for those with large tears (>3cm), 
persistent pain, or shoulder weakness, surgical intervention is typically 
recommended to restore joint mechanics 89.  
 
A B 
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1.2.2 Current Rotator Cuff Repair Techniques 
The current standard of treatment for symptomatic rotator cuff tears includes 
early primary anatomic repair followed by controlled rehabilitation 59. Repair 
procedures most commonly involve arthroscopic tendon-bone fixation techniques 
that rely on suture materials and suture anchors 43,120,172. Regardless of the 
specific suture configuration used, the goal of the surgery is to anatomically 
secure the ruptured tendon to its anatomic footprint to improve shoulder strength 
and function 4,168,172.  While the repair of acute, small to medium tears have had 
suitable outcomes with existing techniques, repair of chronic, large (3-5cm) or 
massive tears (>5cm, 2 tendons) have been associated with significant failure 
rates 7,118,144.  
 
Repairs of chronic rotator cuff injuries often fail to form a robust attachment at the 
tendon-to-bone repair site, making it prone to continued failure 166. Excessive 
tension placed on the initial repair site can gradually pull the healing tendon away 
from the bone, forming a gap that can result in complete repair failure, or a re-
tear 26. Clinical studies have reported unacceptably high re-tear failure rates 
ranging from 20-94% 53,60  depending on the size of tear 33,66,79, tissue quality 
51,67,68,79,85,87,137,138, and time between injury and repair 11,12,19,46,55,74,76. Chronic 
injuries in particular present additional challenges that include significant 
retraction of detached tendon, poor quality of remaining tendon, limited 
vascularization, muscle atrophy, fatty infiltration, and osteolysis at the insertion 
site that can further complicate repair outcomes 33,67,72,187. To reduce the high 
occurrence of re-tears and improve tendon repair outcomes, several tissue-
engineering strategies designed to promote tendon-bone integration and/or 
augment mechanics at the repair site have been developed 7,40,136. 
 
1.2.3 Rotator Cuff Repair: Augmentation with Biologic Scaffolds 
To improve primary repair outcomes of large rotator cuff defects, several 
commercially available biologic and synthetic scaffold devices have been utilized 
to mechanically reinforce and enhance the body’s own healing potential for 
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integrating the tendon to bone 39,147. A recent publication by Ricchetti et al., 
extensively reviews the current basic science and clinical understanding of 
several ECM scaffolds currently used to enhance tendon attachment to bone 136.  
 
Extracellular matrix (ECM)-derived scaffolds are the most widely used scaffolds 
for rotator cuff repair and are commonly derived from acellularized small 
intestinal sub-mucosa (SIS) or dermis tissue, from both allogeneic and 
xenogeneic sources 8,35,41. Used as patches or overlays to augment existing 
suture techniques, these scaffolds aim to provide temporary mechanical support 
to “off-load” the repair site at early time points until sufficient tendon attachment 
has occurred 42,96,97. However, variations in the structural composition of the 
scaffold (i.e. collagen crosslinking) can greatly affect the matrix degradation rates 
in vivo9. The failure to match the scaffold’s degradation rates with a sufficient 
amount and/or quality of new matrix production can result in a weakening of the 
scaffold’s overall mechanical properties and limit its usefulness for repair.  
 
In a recent study performed by Derwin et al., four commercially available ECM 
scaffolds were evaluated at time of repair using a canine infraspinatus tear model 
41. The results of this study showed that the elastic moduli of all four matrices 
were initially an order of magnitude lower than the native canine tendon and, 
upon implantation, rapidly decreased their mechanical properties as a result of 
premature graft resorption. This suggests that the mechanical role of these 
scaffolds for use as an augmenting device and their ability to enhance tendon-
bone attachment may be limited. Additionally, the high compliance associated 
with these materials would likely result in considerable stretching of the material 
under physiologic muscle loading and limit its use in primary rotator cuff repair 41. 
 
In addition to providing a mechanical structure, the ECM scaffold’s natural 
composition, unique 3D structure, and ability for remodeling in vivo may provide 
a chemical and structural environment capable of instructing host cells to 
enhance healing at the site of repair. However, despite encouraging results as a 
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graft patch in animal models, sub-optimal results were observed in human trials 
80,149,171. In a randomized control trial performed by Iannotti et al., augmentation 
with small intestinal submucosa (SIS) failed to improve frequency of re-tear, 
tendon healing, or clinical outcome scores 80. The sub-optimal results have been 
primarily attributed to a mismatch in mechanical properties, rapid matrix 
remodeling found in the chronically degenerated shoulder joint environment, and 
lack of functional tendon-to-bone integration 41. 
 
More recently, free biceps tendon autografts have been used in repair, 
particularly in exceptionally large retracted tears, in which anatomic re-
attachment is impossible 32,117,121,135. However, the use of autogenic tissues, 
especially from most at-risk elderly patients, is limited by tissue availability, donor 
site morbidity, and poor tissue quality.  Additionally, the availability, associated 
costs of processing, and risk of immune response from residual genetic material 
further diminishes the potential use of allogeneic or xenogeneic grafts and 
scaffold tissues for rotator cuff repair 139.  
 
To date, the utilization of tendon grafts and ECM derived materials to improve 
function and integration at the tendon-bone attachment site has encountered 
limited clinical success 31,41. Alternative strategies and factors are needed to 
improve the biological fixation of the tendon to the bone to improve overall 
stability and functionality of the repair. 
 
1.2.4 ACL Injury and Repair 
The anterior cruciate ligament (ACL) connects the femur to the tibia and is the 
most commonly injured ligament of the knee with an estimated 200,000 injuries 
occurring each year in the US, especially in younger female athletes 18 (Figure 
1.2). The ACL mediates load transfer and provides overall knee stability by 
limiting excessive anterior tibial translation and internal knee rotation. The ACL 
does not heal on its own following injury due in part to a lack of vascularization. 
Surgical intervention is often required to restore knee stability. Over 100,000 
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reconstructive surgeries are performed yearly in the US, with expenditures 
exceeding 5 billion dollars 25,124,170.  
 
 
Figure 1.2 Anatomy of the Knee A) Native ACL, and B) Torn ACL 
(http://orthoinfo.aaos.org/topic.cfm?topic=a00549) 
 
Current reconstruction techniques utilize allogeneic or autogenic tendon grafts 
secured into anatomically placed tibial and femoral bone tunnels to restore ACL 
function 116. Grafts most commonly used include the hamstring tendon (HT) graft 
and the bone-patellar tendon-bone (BPTB) graft isolated from the central third of 
the patellotibial junction. However, the higher risk of revision surgery with HT 
grafts and the ability of BPTB grafts, to more effectively integrate with 
subchondral bone of the tunnels have made BPTB grafts the current gold-
standard for repair 50,125.  
 
Despite favorable outcomes following ACL repair, graft failure rates have been 
reported as high as 25% due in part to poor graft fixation 37,45,134. Long-term, 
follow-up studies of ACL reconstructed patients have shown continued knee 
laxity and only a 63% return to pre-injury activity 6. Additionally, the incidence of 
early-onset osteoarthritis (OA) within 7-14 years has been reported as high as 
50% 95,129,145; and more recently, a study by Barenius et al., revealed a 3-fold 
increase in the prevalence of OA after ACL reconstruction compared to the 
contralateral knee 10. 
 
A B 
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Compared to the native ACL, current tendon graft tissues exhibit vastly different 
mechanical and viscoelastic properties that often exceed the native tissue 
stiffness and strength 105,139. Recent evidence suggests that an overly stiff ECM 
can shield the endogenous cells or infiltrating host cells within these structures 
from strains necessary for proper graft-bone integration and growth of new 
ligamentous tissue 49,64,111,127.  Suboptimal tissue mechanics, limited tissue 
availability, and donor-site morbidity associated with the use of autologous grafts, 
as well as the additional risk of disease transmission with allogeneic tissues, has 
led to the development of novel tissue-engineering graft alternatives for ACL 
repair. 
 
Current tissue engineering strategies for ACL repair often rely on the use of 
exogenous scaffold materials to match the native tissue properties 127. Again, the 
over-design of these graft materials for initial strength and stiffness, compounded 
with variable degradation rates and risk of immune rejection, limit their ability to 
integrate with native bone and regenerate the damaged ligament tissue. 
 
Mechanical fixation of tendon grafts to bone is commonly performed with 
interference screws, which often fail to preserve or re-establish the anatomic 
insertion site following surgery. Consequently, the resultant attachment site is 
considered the weak point during early post-operative healing and is prone to 
pullout failure under normal knee motion 100,113,140,142. Regeneration of the native 
tissue interface is important for improving graft strength and maturation of healing 
tissue and is critical for restoring normal knee kinematics and improving long-
term outcomes following repair 101. 
 
1.3 Tendon/Ligament to Bone Interface - Enthesis 
1.3.1 Enthesis Structure and Function 
Tendons (connecting muscle to bone) and ligaments (connecting bone to bone) 
attach to the bone via an indirect or direct insertion site 16. Indirect insertions, 
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also known as fibrous insertions, superficially attach the tendon or ligament to the 
bone via the periosteum and are characterized by collagenous fibers known as 
Sharpey’s fibers that traverse directly from the tendon or ligament deep into the 
bone 126. Fibrous attachments are often broad, distributing force over a large 
area and reducing stress concentration at the interface. Examples of indirect 
entheses include the medial collateral ligament (MCL) and the deltoid tendon 
insertion of the humerus. 
 
Direct insertion sites are characterized by a heterogeneous and regional 
distribution of cells, matrix, and mineral content 100,148,155,166. The composition and 
structure of this insertion site is shared by both rotator cuff tendons of the 
shoulder and cruciate ligaments of the knee and are considered biochemically 
and morphologically similar 36,179. Direct entheses connect the tendon or ligament 
to bone via a characteristic fibrocartilage region over a length of approximately 
100µm-1mm. 180. This interface, also referred to as a fibrocartilaginous insertion, 
exhibits a functionally graded zonal arrangement composed of four regions that 
include: 1) tendon or ligament, 2) un-mineralized fibrocartilage, 3) mineralized 
fibrocartilage, and 4) bone (Figure 1.3) 15,16,180. 
 
Figure 1.3 Structural and Compositional Zonal Arrangement of the Enthesis 
(http://omicsonline.org/2161-0533/2161-0533-S1-003.php?aid=4930) 
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The tendon or ligament (zone 1) consists of elongated, spindle-shaped 
fibroblasts embedded in a highly aligned extracellular matrix (ECM) composed of 
primarily type I collagen with small amounts of type III and V collagen, elastin, 
and proteoglycans such as decorin 88. The un-mineralized fibrocartilage region 
(zone 2) contains ovoid fibrochondrocytes and consists of type II, and III collagen 
with small amounts of type I, IX, and X collagen along with the proteoglycans 
aggrecan and decorin 165. The mineralized fibrocartilage region (zone 3) contains 
hypertrophic fibrochondrocytes and significant amounts of type I, II and X 
collagen and aggrecan. Calcium phosphate crystals and mineral deposits are 
also contained within this region 148,155. Collagen fibril alignment is more 
disorganized here compared to both tendon and un-mineralized fibrocartilage 
regions 164. The border between mineralized and non-mineralized 
fibrocartilaginous regions is identified by a ‘‘tidemark’’, a basophilic line that 
represents the mineralization front. The last region, bone (zone 4), consists of 
osteoblasts, osteocytes and osteoclasts and is mainly composed of type 1 
collagen and a large mineral content 165.  
 
The mechanical properties of bone and tendon are significantly different. Bone is 
stiff with a modulus of 20 GPa whereas tendon is extensible with a stiffness 
around 200 MPa 162. The presence of a fibrocartilaginous transition region is 
designed to reduce stress concentrations that would otherwise form at the 
interface of two dissimilar materials 150,164.  
 
The varied mechanical properties across the tendon/ligament insertion site are 
related to gradations in collagen fiber orientation and mineral content. Highly 
aligned collagen fibers become more disorganized across the insertion as the 
fibers angularly integrate with the bone, reducing tissue stiffness (Figure 4) 164. 
This structural gradation results in a region between tendon and bone that is 
approximately half as stiff as the tendon 100. The compliance of the region 
between tendon and bone may serve to dissipate energy during load transfer and 
help prevent injury 61,100. Nearer to the bone region, the increasing mineral 
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content of the insertion site causes stiffening of the collagen fibers and increases 
tissue stiffness approaching that of the bone 61. 
 
Interdigitation of the fibrocartilage region with the bone increases the surface 
area of the attachment and, along with its ability to resist changes in cross-
sectional area, is thought to reduce stress concentrations at this interface 61. 
Additionally, the structural and mechanical differences across this zone gradually 
dissipate fiber bending and stretch-induced narrowing of the tendon that can 
arise during movement away from the tendon-bone junction 14,17,150. As a result, 
the likelihood of failure of the fibrocartilaginous zone, if healthy, is drastically 
reduced with failure occurring more often in the tendon/ligament region or 
subchondral bone 57.  
 
1.3.2 Enthesis Healing Following Repair 
The structure and function of the native enthesis is essential for mediating load at 
the tendon/ligament bone interface. As such, its regeneration following repair is 
critical for optimal outcomes. Failure to regenerate may leave the attachment site 
prone to failure, limiting clinical outcomes such as the return of normal shoulder 
function 61,93. 
 
Despite efforts to improve tendon-bone healing, current rotator cuff repair 
practices involving suture with or without scaffold augmentation fail to restore the 
native enthesis 101,141. Instead, current mechanical fixation techniques develop a 
disorganized fibrovascular tissue with inferior mechanical properties between the 
tendon and bone 29,56,141,166 (Figure 1.4). The loss of this complex 
fibrocartilaginous insertion at the tendon-bone interface has been implicated in 
the high frequency of tendon re-tears following primary rotator cuff repair 
74,100,122,164.  
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Figure 1.4 Safranin O Staining of RC Enthesis A) Native RC enthesis, and B) RC enthesis 
following suture repair. 
 
Formation of this fibrous tissue following repair occurs over three stages: 
inflammation (0-7 days), repair (5-14 days), and remodeling (>14 days) 100. First, 
in the inflammation stage, a substantial infiltration of fibroblast and inflammatory 
cells occurs at the site of injury and increases angiogenesis. The ECM contains 
some cartilage-like cells and is composed of primarily fibronectin, 
glycosaminoglycans, and type III collagen 163. Collagen fiber orientation and 
tensile mechanical properties of the tendon are significantly decreased, resulting 
in no integration with bone and the lack of a fibrocartilage insertion zone.  
 
During the repair stage, collagen fibers begin to integrate with the bone but 
overall tissue quality remains poor and disorganized compared to native 63. The 
tissue is composed of granulation tissue and contains chondrocyte-like cells and 
fibroblasts 56. Several growth factors are up-regulated to induce cell proliferation 
and matrix deposition at the site of repair including fibroblast growth factor basic 
(FGF-b), bone morphogenetic proteins (BMP-12 -13, and -14), platelet derived 
growth factor-B (PDGF-B), and transforming growth factor-B1 (TGF-B1) 181.   
 
In the remodeling stage, the newly formed tissue remains disorganized and 
hypercellular 62.  Following 4 weeks repair in a rat model, the tendon had 
integrated with bone but no fibrocartilage region was observed 62. At 8 weeks, the 
repair site was more organized than previous time points but did not resemble 
the graded fibrocartilage structure of the native enthesis 163. Although structural 
B A 
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properties reached two thirds of normal levels, the material properties of the 
tissue remained an order of magnitude weaker than in control groups 29. By 16 
weeks, the healing tissue still had not functionally integrated with the bone. The 
tendon attached to the bone through a fibrovascular scar with a sharp boundary 
between soft tissue and bone and was structurally and compositionally different 
than the native enthesis tissue 3,101. 
 
Like the rotator cuff, repair of the ACL with current grafting techniques also fails 
to recreate a fibrocartilaginous enthesis. Instead, the graft often heals with a 
fibrovascular scar at the graft-tunnel interface that exhibits poor mechanical 
stability and remains a primary cause of ACL graft failure 2. Furthermore, 
suboptimal long-term ACL outcomes and increased risk of OA may be due in part 
to poor graft-bone integration and an inability to effectively transfer load 48. As 
such, the re-establishment of a native-like enthesis is crucial for improving the 
long-term success and functionality of the reconstructed knee. 
 
As described, current surgical procedures for both rotator cuff and ACL repairs 
fail to regenerate the compositional, geometrical, and biomechanical properties 
of the native enthesis to the level needed for normal joint function and tissue 
regeneration 126. As a result, researchers have begun to design new strategies 
focused on recreating the functional properties of the native enthesis to improve 
repair success and improve long-term outcomes 98,154. 
 
1.3.3 Native Enthesis Development 
Understanding the biological and mechanical processes regulating the 
development of the native tendon-bone interface may be useful in identifying new 
tissue engineering strategies for improving enthesis repair. In a recent in situ 
hybridization study by Galatz et al., the spatial and temporal expression of ECM 
genes involved in rotator cuff development were examined utilizing a murine 
model 52. The study reports the formation of tendon and bone masses at 15.5 
days post-conception but a transition zone was not observed until 7 days after 
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birth. Furthermore, significant enthesis maturation did not occur until day 21 
postnatally. The formation of a direct insertion site is believed to occur through 
endochondral ossification. The tendon/ligament initially attaches to the hyaline 
cartilage of bone and as ossification occurs, a fibrocartilaginous region develops 
at the tendon-bone interface. The formation of this fibrocartilage zone is due to 
fibroblast metaplasia as a result of mechanical stimuli at the insertion site 83,167. 
The influence that mechanical load has on enthesis formation during post-natal 
development underlines the important role mechanical stimuli may play in 
regenerating the insertion site during repair. 
 
In a separate study, muscle loading during tendon enthesis development has 
been shown to significantly impact insertion maturation in a murine model 77. 
Botulinum toxin injection, which causes muscle paralysis, resulted in less 
mineralization, impaired fibrocartilage formation, diminished collagen alignment, 
and inferior mechanical properties compared to saline controls at post-natal time 
points 77. However, paralysis at early time points did not result in significant 
differences in enthesis structure suggesting that mechanical load is not needed 
for initiation of enthesis development but is a critical factor in directing enthesis 
maturation 77. 
 
In addition to mechanical cues, chemical factors are also known to be important 
in enthesis development. Proteins including Indian hedgehog (Ihh) and 
parathyroid hormone-related protein (PTHrP) have been implicated in regulating 
chondrocyte hypertrophy and mineralization100,162. Graded expression of these 
factors at the tendon-bone interface may regulate spatial gradients between 
mineral and un-mineralized fibrocartilage zones162. Transcription factors SOX-9 
and scleraxis (Scx) are associated with chondrogenesis and tenogenesis 
respectively 152,160. Cells forming the insertion site originate from both SOX-9 and 
Scx lineages and the localization of these genes at the tendon-bone interface 
defines the tendon/fibrocartilage transition 160. Scx expression at this site has 
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also been shown to regulate BMP-4 expression in tendon cells. Inhibition of 
BMP-4 expression in Scx positive cells failed to initiate enthesis development 21.  
 
The combination of these works demonstrates that the development of a 
functionally graded enthesis is driven by and responsive to both biologic and 
mechanical signals. As such, tissue-engineering strategies targeting these 
signaling pathways post-injury may be useful for stimulating the required cells, 
ECM, and mechanical properties necessary for native-like repair. 
 
1.4 Strategies to Improve Tendon-Bone Healing In Vivo 
Recent tissue-engineering approaches to improve soft-tissue/bone healing at the 
tendon-bone interface are typically designed to augment current repair 
techniques in vivo. Treatments often rely on the singular or combined use of 
growth factors and cells with existing suture or scaffold-augmented fixation 
techniques to modulate the repair site and facilitate the formation of the native 
insertion site. These biologic approaches have been extensively reviewed by 
several researchers3,13,114. Examples of specific applications as they relate to 
rotator cuff repair are described below: 
 
1.4.1 Growth Factor Therapies 
To enhance rotator cuff healing in vivo, the application of various growth factors 
capable of modulating the biology at site of repair have been investigated 114. 
Fibroblast growth factor basic (FGF-2) is known to stimulate angiogenesis as well 
as influence matrix synthesis and is up-regulated during early stages of tendon 
healing 3,71. Local application of FGF-2 in a fibrin sealant following acute injury 
and repair of the supraspinatus tendon in a rat model resulted in accelerated 
healing at the tendon-bone interface compared to the fibrin sealant alone in the 
contralateral shoulder 81. At 2 weeks, histological scorings of repair sites 
demonstrated improved cellularity, vascularity, and fiber maturity and were 
correlated with improved mechanical strength when compared to fibrin only 
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treatment. However, differences were not observed at the later 4 and 6 week 
time points. Additionally, despite the improvement in attachment strength, a 
fibrocartilaginous region characteristic of the native tendon-bone interface was 
not recreated.  
 
In a similar study by the same group, FGF-2 fibrin sealant was applied to a rat 
tendon-bone interface and repaired with a commercially available acelluarized 
dermal graft (GraftJacket)82. At 2 weeks, repair with FGF-2 showed similar 
histological scores and strength compared to graft repairs without growth factor. 
However at 6 and 12 weeks, repair with FGF-2 formed a cartilaginous tissue at 
the tendon-bone interface accompanied with improved repair failure strength. 
Despite the presence of fibrocartilage, the insertion site still did not recreate the 
complexity of the direct insertion found in the unoperated control shoulders. 
 
TGF-B isoforms have also been shown to alter healing at the tendon-bone 
interface with varied results 84. Application of TGF-B1 (and suppression of 
isoforms 2 and 3) at repair sites resulted in increased fibrous scar tissue 
formation and a decrease in mechanical properties; while the use of TGF-B3 and 
suppression of isoforms 1 and 2, resulted in no significant change compared to 
controls. In a separate study, however, prolonged exposure to TGF-B3 in a 
heparin/fibrin-based delivery system positively enhanced the structural and 
material properties of the tendon-bone interface following repair 107. Decreased 
scar formation and increased fibrocartilage formation, collagen alignment, and 
interface strength have also been reported with the use TGF-B3 administered at 
site of repair within osteoconductive calcium-phosphate matrix86. 
 
In vivo, growth factor signaling pathways may be regulated and may interact with 
each other to coordinate control of cell function. FGF-2, for example, is known to 
alter gene expression of several growth downstream factors including TGF-B and 
BMP-2 13. As such, signaling of a single growth factor is unlikely to mediate 
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native-like tissue regeneration alone and has led researchers to the use of 
platelet rich plasma (PRP) therapies to improve enthesis repair. 
 
PRP, isolated from autologous blood, forms a dense plasma matrix that can be 
applied at the repair site. PRP is known to contain several growth factors that 
have been shown to play a critical role in the tendon healing process including: 
TGF-B, bFGF, PDGF, vascular endothelial growth factor, connective tissue 
growth factor, and epidermal growth factor 3. In a recent study by Ersen et al., the 
use of PRP in a rat supraspinatus tear model resulted in improved load to failure 
and stiffness at the repair site 47. However, histological differences were not 
observed between groups repair treated with and without PRP.  
 
While the use of growth factor based strategies commonly results in increased 
matrix synthesis and structural improvements at the repair site, the resultant 
tissue often consists of fibrous scar tissue rather than an organized, fibrocartilage 
gradient characteristic of the native enthesis. Further optimization related to the 
mode of delivery, timing of release, and ideal concentrations is needed for these 
strategies to be successful. As such, surgeons continue to rely on existing suture 
fixation techniques with sub-optimal outcomes. Alternative cell-based therapies, 
capable of sensing and responding to the local chemical and mechanical 
environments, may be needed to improve enthesis repair. 
 
1.4.2 Cell-Based Therapies 
One of the most common cells used in current cell-based therapies is the 
mesenchymal stem cell (MSC). MSCs are characterized by their unique ability to 
self-renew and differentiate in vitro into several different specialized tissue 
lineages including bone, tendon, cartilage, muscle, ligament, and adipose tissue 
27,184. MSCs can be easily isolated from an autologous or allogeneic bone 
marrow aspiration and are considered to be anti-inflammatory and/or immuno-
modulatory upon implantation. More recently, resident MSC populations have 
also been harvested from adipose tissues which may be a more accessible 
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donor source for MSC isolation 44. In vivo, MSCs are capable of directly 
participating in the healing response or signaling local or distant host processes. 
 
The use of MSCs to improve tendon-bone healing following rotator cuff injury has 
recently been examined in a rat model 69. Following the detachment of the 
supraspinatus tendon, bone marrow derived MSC contained in a fibrin sealant 
carrier were injected into the repair site and the tendon subsequently repaired 
with suture 69. Results, at both 2 and 4 week time points, showed no histological 
difference in cartilage formation, collagen orientation, failure strength, or stiffness 
of the enthesis compared to controls 69. Additional signals or differentiation 
factors are likely needed for effective interface repair. Undifferentiated MSC 
alone may not be enough to stimulate the desired regenerative response.  
 
In a follow-up study also performed by Gulotta et al., MSCs were transduced with 
adenoviral-mediated scleraxis, a transcription factor implicated in tenogenesis 
and native enthesis development, before being integrated into a fibrin sealant 
carrier and injected into the repair site70. Despite the lack of histological 
improvement at 2 weeks following repair, increases in both load to failure and 
stiffness were observed compared to non-transduced MSC injected controls. At 4 
weeks, the biomechanics continued to improve, and histologically, the formation 
of fibrocartilage was observed at the tendon-bone interface. However, the 
organization of this tissue and amount of fibrocartilage present was still 
significantly less than in the native enthesis. Nonetheless, the application of 
differentiated MSCs may be a useful tool for inducing the native healing response 
following rotator cuff repair and holds promise for future cell-based strategies 
utilizing these cells. 
 
Despite the potential of the described in vivo techniques to improve tissue 
healing at the tendon-bone interface, many of these strategies continue to rely on 
existing suture-fixation techniques and frequently fail to re-create the native 
anatomy of the rotator cuff enthesis. The inability to restore this interface 
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compromises repair success and long-term clinical outcomes following 
tendon/ligament injury 99. As such, novel tissue engineering approaches capable 
of regenerating the graded fibrocartilaginous structure and mechanics of the 
native enthesis are needed for orthopedic repair. 
 
1.5 In Vitro Scaffold-Based Strategies for Enthesis Repair 
To improve regeneration of the tendon-bone insertion site following repair, 
several in vitro tissue-engineering strategies have been developed to replicate 
the functionally graded properties of the enthesis for subsequent implantation in 
vivo 186. These approaches mimic the zonal arrangement of the native tissue by 
imploring stratified or graded scaffold designs described in the following sections 
154. 
 
1.5.1 Stratified Scaffold Designs 
Stratified scaffold designs for enthesis regeneration typically consist of various 
cells, growth factors, or other signals continuously arranged in pre-defined 
regions specific for the generation of distinct tissue types. The goals of stratified 
scaffold designs are to integrate these regions and form a graded 
fibrocartilaginous transition zone following implantation. Work by Spalazzi et al., 
successfully produced a co-cultured 3D scaffold composed of three distinct but 
continuous phases arranged in succession. The first phase served as the tendon 
region and consisted of poly- (lactic-co-glycolic acid) (PLGA) (10:90) matrix 
seeded with ACL derived fibroblasts 158,159.  The second region was the 
fibrocartilaginous region composed of PLGA (85:15) and seeded with 
chondrocytes. The third region served as the bone region and was composed of 
sintered PLGA (85:10) and 45S5 glass microspheres and was seeded with 
osteoblasts. Deposition of collagen 1 was observed throughout the tendon and 
fibrocartilage regions with significant amounts of mineral in the bone region. 
Subcutaneous implantation of the constructs resulted in continuity across all 
three phases with mineralized tissue in the bone regions and distinct 
 21 
fibrocartilage and tendon regions 156,157. The results of these studies 
demonstrated the ability of a multi-phasic construct consisting of appropriate cells 
and matrix composition to form a functionally graded tissue following 
implantation. However, the ability of this stratified scaffold to integrate with the 
host or grafted tissue in a tendon/ligament repair model has not been evaluated. 
Moreover, the utilization of scaffold materials with variable degradation rates and 
mechanical properties may shield the cells from signals required for optimal 
tissue regeneration upon implantation. 
 
Paxton et al. describes an alternative scaffold design for the creation of a whole 
multi-tissue construct composed of an artificial ligament mid-substance attached 
between two osteoconductive anchors 123. Fibroblasts seeded into a fibril gel are 
guided through cell-mediated tension around two bio-resorbable bone cement 
anchors (Brushite) producing ligament/bone-like tissue interfaces. Increasing the 
collagen content of the ligament region, through the addition of growth factors 
(ascorbic acid, proline, and TGF-B), led to an increase in the attachment strength 
at this interface. The ability of this strategy to form a ligament mid-substance and 
two relevant ligament/bone interfaces allows this technology to directly replace 
the damaged tissue at the site of repair eliminating the need to integrate with the 
damaged tendon/ligament tissue or replacement tendon graft. However, the 
ability of this construct to regenerate a fibrocartilaginous enthesis following 
implantation has not been evaluated. 
 
1.5.2 Graded Scaffold Designs 
Opposed to stratified scaffold designs that rely on integration of distinct, pre-
defined regions upon implantation to recreate the graded properties of the 
enthesis, graded scaffold designs utilize spatially arranged biochemical or 
biophysical signals to gradually control cell differentiation and matrix synthesis in 
vitro. In a study performed by Phillis et al., fibroblasts were seeded onto a 
scaffold substrate conjugated with a linearly graded increase of a bone 
transcription factor, Runx2. Regions of low Runx2 concentration were associated 
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with more tendon-like phenotype, while higher concentrations trans-differentiated 
towards osteoblast-like cells 128. The results showed a gradual change in 
phenotype over the length of the scaffold. However, the formation of a 
fibrocartilaginous transition was not recreated. 
 
In a similar study, MSC were cultured onto a polymeric scaffold to engineer 
composite osteochondral tissues 174. Silk microspheres formed two inversely 
proportional linear gradients across the construct controlling the delivery of BMP-
2 and IGF-1. The proximal and distal ends of the scaffold contained the highest 
concentrations of BMP-2 and IGF-1, respectively, which both decreased across 
the construct length. This gradual change of local growth factor release resulted 
in graded differences of calcium and glycosaminoglycan (GAG) deposition, 
characteristic of bone and cartilage regions, respectively. Collagen type-I, II, and 
X gene expressions were also similarly graded across the two construct regions, 
mimicking the native composition of the osteochondral interface. The results of 
this study validate the ability of controlled growth factor release to generate 
tissue gradients in vitro and may be applicable in generation of other tissue 
interfaces such as the tendon-bone interface. 
 
Biophysical gradients can also be used to form functionally graded interface 
tissues in vitro 92,186. In a study by Li et al., a mineralization gradient of calcium 
phosphate was incorporated into electrospun PLGA nanofibers 91. The formation 
of this gradient was associated with stiffness variations across the scaffold 
length. Seeding this scaffold with adipose-derived MSCs resulted in the graded 
expression of osteogenic cell markers, with regions of highest stiffness and 
mineral content being most bone-like. Interestingly, formation of this osteogenic 
gradient was achieved without osteogenic inducing culture medium suggesting 
that compositional and mechanical gradations alone may be sufficient to promote 
cell differentiation and influence cell behavior. 
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Each of the scaffold-based strategies described emphasize the influence local 
environmental factors (generated in vitro or following implantation) have on the 
formation of graded tissue properties. However, use of these strategies (stratified 
or graded in design) is limited as they are routinely designed to match the native 
properties of the tendon, bone, and/or insertion site, potentially shielding the 
repair site from signals necessary for proper enthesis regeneration. Additionally, 
the degeneration of the scaffold material often does not match the rate of new 
tissue synthesis and can impair the rate and course of new tissue development 
and maturation. Furthermore, the use of exogenous scaffolding materials can 
trigger a foreign body reaction leading to material rejection and/or increased 
amounts of fibrotic scar tissue at site of repair. 
 
Due to these imitations and the inability of current scaffold-techniques to fully 
regenerate native enthesis following repair, alternative tissue engineering 
strategies are needed.  A scaffold-less method to engineer an initially compliant 
multi-phasic tissue graft, composed of physiologically relevant tissue interfaces 
and capable of sensing and responding to local environmental signals, may be 
well suited for regeneration of the native functional tendon-bone interface. 
 
1.6 Scaffold-less Tissue Engineering – STEL Approach 
Previous work from our lab, the Skeletal Tissue Engineering Laboratory (STEL), 
has demonstrated the successful fabrication of a multiphasic bone-ligament-bone 
(BLB) graft for ligament repair, without the use of exogenous or stiff, scaffolding 
materials 104,105. Regionally distinct areas of bone and ligament form viable tissue 
interfaces in vitro that are capable of quickly remodeling upon implantation. 
(Figure 1.5) 
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Figure 1.5 Scaffold-Less BLB Construct 
 
The utilization of this initially compliant graft in both medial collateral (MCL) and 
anterior cruciate ligament (ACL) repair models has shown that the graft quickly 
incorporates into native tissue and develops a viable enthesis shortly following 
repair 105. Significant improvements in construct size, composition, morphology, 
and mechanics were observed at increased ACL recovery time points, as 
described in the work of Ma et al. 106. Briefly, BLB outcomes, following 6 months 
recovery, restored approximately 52% of native tissue modulus and were 
histologically similar to the native ACL tissue. Results at later 9 month recovery 
time points compared to existing autologous patella tendon graft techniques, 
demonstrated superior tissue regeneration and knee mechanics 106.  
 
However, despite the success of this BLB tissue in an ACL repair model, the 
translation of these results to a rotator cuff repair model is unknown. Additionally, 
to further the advancement of this technology towards clinical use, a regulatory 
compliant, standardized, and commercially viable manufacturing process is 
needed. Achievement of these goals could significantly streamline the long-term 
success of this tissue engineering product for both tendon and ligament repair. 
 
1.7 Summary 
The approach, outlined in the aforementioned aims, seeks to advance the 
commercial manufacturing and clinical translation of a compliant multi-phasic 
tissue construct for tendon/ligament repair. The use of a compliant scaffold-free 
graft that can respond to local mechanical and biological environments has the 
potential to improve tendon/ligament-to-bone regeneration and subsequent repair 
outcomes following rotator cuff and ACL injury. However, despite considerable 
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amounts of research in the field and the development of numerous tissue-
engineering strategies, there are relatively few products currently available to 
patients or in late-stage clinical trials. This slow progress in development is due 
part to a lack of proficiency in translating bench-scale methods to robust, cost-
effective manufacturing processes that comply with current good manufacturing 
processes (CGMP) guidelines and ensure the reproducibility, efficacy, and safety 
of the final tissue engineering product for human use. 
 
Utilizing a rat model, Chapter 2 of this thesis, will evaluate the efficacy of our 
scaffold-less construct to regenerate the native enthesis following an acute, and 
more clinically relevant, chronic, full thickness supraspinatus tear. It is 
hypothesized that utilization of our construct will regenerate an enthesis that 
more closely resembles the native structural properties compared to current 
suture repair techniques.  
 
Next, Chapter 3 and Chapter 4 will describe the advancement of existing 
laboratory protocols for the production of uniform, reproducible, and clinically 
relevant scaffold-less constructs. The development of such a well-characterized 
system will provide consistent, high-quality constructs and lessen the difficulty for 
adapting fabrication methodologies into CGMP-compliant and scalable 
manufacturing processes required for human use.  
 
Chapter 5 will describe the translation of the reproducible bench-scale 
manufacturing processes of Chapter 3 into a novel bioreactor system for semi-
closed, automated BLB fabrication. The development of this bioreactor will 
minimize contamination risk, eliminate user-variability, and provide means to 
economically scale construct production for commercial construct use. 
 
In summary, this thesis describes a novel treatment strategy for the regeneration 
of the tendon/ligament-to-bone interface, which may be critical for improving 
current rotator cuff repair outcomes following injury. These findings may provide 
 26 
a new paradigm for the treatment of other musculoskeletal injuries requiring the 
reattachment of soft-tissue-to-bone. Furthermore, the approach outlined in this 
report for scaffold-less construct manufacturing demonstrates the practicality of 
employing translatable and scalable processes early in the product development 
stage as a means to overcome existing challenges in the commercialization and 
clinical advancement of new tissue engineering technologies.  
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Chapter 2  
Utilization of Scaffold-less Constructs for Tendon-Bone 
Interface Regeneration 
2.1 Introduction 
Rotator cuff (RC) tears are one of the most common orthopedic disorders in the 
US with over 70,000 repair procedures performed annually 169. Tears of the 
rotator cuff tendons often fail to heal spontaneously and are frequently the cause 
of significant shoulder pain and impaired shoulder function 114. Current repair 
techniques utilize an open or arthroscopic suture technique to reattach the 
tendon to bone. Failure rates, however, especially in full thickness large (3-5cm) 
or massive tears (>5cm, 2 tendons), are unacceptably high (20-94%) 53,108. 
Complications including tendon retraction, muscle atrophy, and fatty infiltration 
have been known to limit the successfulness of the repair 33,67,72,187. Additionally, 
healing of the tendon-bone insertion (enthesis) with current techniques often 
results in a notably weaker fibrovascular scar rather than a normal enthesis and 
may explain the high prevalence of repair failures 26. 
 
The native enthesis consists of a compositionally and mechanically graded 
fibrocartilage transition zone designed to minimize stress concentrations at the 
tendon-bone interface. Using a rat supraspinatus rotator cuff model, 
Thomopoulos et al., demonstrated that the biology and zonal arrangement of the 
enthesis is not regenerated following rotator cuff repair 166. Rather, a sharp 
boundary was histologically observed, with disorganized collagen fibers and a 
fibrocartilaginous region, representing a significant deviation from the native 
enthesis anatomy. The structural repair and regeneration of a native enthesis 
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and return of normal biomechanics is paramount for improving functional 
outcomes and reducing the risk of recurrent structural failure after repair. As such, 
several tissue-engineering approaches have been developed to improve the 
biological healing and regeneration of the enthesis following RC repair.  
 
To improve the healing response at the enthesis, Derwin et al. described several 
commercially available extracellular matrix (ECM) scaffolds currently used 
clinically for rotator cuff repair 41. While the inherent biochemical properties of 
these scaffold materials have the potential to modulate host processes and 
influence the biology of the repair, the scaffold’s properties, which are degraded 
over time, often do not match the rate of new extracellular matrix production. 
Additionally, a structurally native fibrocartilage enthesis often fails to regenerate 
and, as such, alternative strategies are needed to improve enthesis repair of 
rotator cuff injuries. 
 
More recently, stratified and functionally graded scaffold-based approaches have 
been developed to pre-engineer the native tendon/ligament-to-bone interface in 
vitro 154,186. In these studies, the spatial distribution of mechanical properties, 
biological factors, and/or cell populations are used to direct the formation of 
gradients designed to mimic the tendon insertion site in vitro or following 
subcutaneous implantation. Evaluation of these graded scaffolds in an in vivo 
rotator cuff repair model, however, has not been performed, and the degradation 
characteristics of the scaffold and biocompatibility has not been defined to date. 
 
As an alternative to current scaffold based approaches, our lab has developed an 
initially compliant, scaffold-less tissue engineered bone-ligament-bone construct 
that relies on the local biologic and mechanical environments to direct the 
regeneration of the tendon or ligament-to-bone insertion. Previous work in sheep 
ACL and rat MCL repair models have shown that the osteogenic regions of our 
construct quickly integrate with the host tissue and rapidly remodel forming a 
graded tendon/ligament-to-bone transition that undergoes hypertrophy to match 
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the native footprint (Figure 2.1). 
 
 
Figure 2.1 Ligament/Bone Interface of BLB Construct Explant A) H&E showing ligament 
integration into bone through Sharpey’s fibers (arrow) and fibrocartilage-like region at 2-
months, B) Alizarin Red staining of ligament -bone interface showing mineralization 
gradient at 2 months, and C) Femoral insertion of explanted BLB graft at 9-months. 
Construct diameter significantly increased in size from initial construct diameter (approx. 
3mm). 
 
While the results of these studies in the ACL are encouraging, it is unclear if they 
can be extrapolated to a rotator cuff model. The objective of this study was to 
evaluate the efficacy of our osteogenic scaffold-less constructs to regenerate the 
native matrix organization and mechanical strength of the enthesis in both acute 
(immediate repair) and chronic (repair 4 weeks post injury) supraspinatus tears in 
a rat model. We hypothesized that utilization of the tissue-engineered tendon 
construct would better regenerate the fibrocartilage transition zone, collagen 
organization, and tendon attachment strength of the native enthesis in both acute 
and chronic tear repairs compared to suture repair alone.  
 
2.2 Materials & Methods 
2.2.1 Animal Model & Design 
The University of Michigan Institutional Animal Care and Use Committee 
(IACUC) approved this study. Female Fisher 344 rats, approximately 150-200 g 
in mass, were used in this study. For recreating an acute supraspinatus tendon 
tear, right shoulders underwent a full thickness supraspinatus tenectomy using a 
transacromial approach 29. Chronic supraspinatus tendon tears were created by 
encasing the detached end of the supraspinatus tendon in a small piece of 
A B C 
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silicone tubing and allowing the animal to recover for 4 weeks. The encasement 
with the silicone tubing prevented attachment to the surrounding connective 
tissue so that the cut end of the tendon could easily be identified and repaired at 
a later date. The left contralateral shoulders were used as non-surgical controls 
for each treatment group. Both acute and chronic tendon tears were repaired 
with either a Mason-Allen suture technique (suture repair group) or a modified 
trans-osseous technique utilizing a tissue engineered construct (construct repair 
group). At 8 weeks (n=43) following repair of the tendon, animals were 
euthanized with an overdose of sodium pentobarbital and assessed for 
biomechanical and structural repair of the injury site.  
 
2.2.2 Preparation of Solutions and Media 
All media and solutions were prepared and stored at 4°C prior to use. Media 
were warmed in a heated water bath to 37°C before utilized in the culture of cells. 
Media were prepared, as previously described, with slight modifications 104,153. 
Growth medium (GM) consisted of Dulbecco’s Modified Eagle Medium (DMEM; 
Gibco, Rockville, MD, Cat# 10565-042) supplemented with 20% Fetal Bovine 
Serum (FBS; Gibco, Rockville, MD, Cat# 10437-028) and 2% antibiotic-
antimycotic (Sigma, St. Louis, MO, Cat# A9909). Osteogenic GM consisted of 
GM supplemented with 600ng/ml bFGF, and 40 ng/ml dexamethasone. 
Differentiation medium (DM) consisted of DMEM supplemented with 7% Horse 
Serum Albumin (HS, Gibco, Rockville, MD, Cat# 16050-122) and 2% antibiotic-
antimycotic. Osteogenic DM consisted of DM, plus the addition of 0.13 mg/ml 
ascorbic acid-2 phosphate, 0.05 mg/ml L-proline, 400 ng/ml dexamethasone and 
2 ng/ml transforming growth factor-beta (TGF-b; Peprotech, Rocky Hill, NJ, Cat# 
100-21).  
 
2.2.3 Bone Marrow Isolation and Cell Expansion 
Bone marrow stromal cells were isolated and expanded according to a previously 
described protocol 104,153. Briefly, rat femurs were removed from the animal and 
cut at the proximal and distal metaphysis. The marrow contents were extracted 
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through centrifugation (900 g for 10 min) and cultured on 100 mm tissue culture 
treated polystyrene plates (BD Falcon). Plates were fed osteogenic GM and 
incubated at 37°C, 95% humidity, and 5% CO2. After 72 hours, plates were 
rinsed with DPBS and fed with fresh GM, removing the non-adherent cells. The 
remaining adherent cell population was cultured to 80% confluence, at which 
time cells were enzymatically removed from the 100 mm plate using a 0.25% 
trypsin-EDTA solution (Gibco), passaged, and seeded onto 100 mm plates at a 
density of 5 x 103 cells/cm2. Following 3-4 passages, the cultured cells were 
utilized for construct fabrication. 
 
2.2.4 Preparation of Self-Organized Constructs 
Methods for creating scaffold-less three-dimensional tissues have been 
previously described by our lab 104,105,153. Bone-like constructs, instead of 
tendon/ligament-like constructs, were used in this study based on their ability to 
specifically regenerate the tendon-bone interface in an ACL repair model. Briefly, 
MSCs plated onto 100 mm cell culture dishes at 21x103 cells/cm2 and suspended 
in 8 mls of osteogenic GM supplemented with 0.13 mg/ml ascorbic acid-2 
phosphate and 0.05 mg/ml L-proline. The dishes were placed in a 37°C, 5% CO2 
incubator and medium changed every 2–3 days. After approximately 5 days, the 
cells became confluent and osteogenic differentiation medium (DM) was 
substituted for GM to induce monolayer delamination. As the monolayer 
delaminated, it was transferred to a Sylgard coated dish and constrained 
between two minutien pins placed approximately 60 mm apart. The monolayer 
was fully self-assembled into a 60 mm long cylindrical construct within 1-2 days. 
One week following delamination, constructs were approximately 0.9 mm in 
diameter and cut into 6 mm long segments for use in rotator cuff repairs (Figure 
2.2A). The medium was again changed every 2-3 days until the construct was 
used for implantation. 
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2.2.5 Surgical Technique 
Rats were anaesthetized using 2% isoflurane and the right shoulder was shaved 
and scrubbed with povidone iodine. An incision was made from a point 2-3 mm 
distal to the head on the humerus to approximately 5 mm proximal along the 
deltoid muscle. The biceps muscle and deltoid muscle were cut longitudinally to 
expose the supraspinatus muscle. The acromion was cut and moved to expose 
the enthesis of the supraspinatus on the humeral head. The supraspinatus was 
isolated and a sagittal cut was made at the tendon-bone interface, detaching the 
tendon from its insertion. For suture repairs, two 0.6 mm crossing tunnels were 
drilled into the greater tuberosity footprint. A 4-0 Vicryl suture (Ethilon) was used 
to suture the detached supraspinatus tendon back onto its original insertion point. 
For the construct repairs, a 0.9 mm bone tunnel was drilled directly through the 
middle of supraspinatus insertion footprint and guided out to the lateral aspect of 
the humeral head. A tissue-engineered graft (~6 mm in length) was pulled into 
the bone tunnel and anchored to the periosteum on the lateral aspect of the 
humerus with 9-0 silk sutures (Ethilon) (Figure 2.2 B).  
 
 
Figure 2.2 In vitro Tissue Engineered Constructs A) Construct prior to implantation and B) 
Construct inserted into humeral bone tunnel during repair of acute rotator cuff tear. 
 
A small hole was made in the remaining supraspinatus tendon with #5 forceps 
and the construct was pulled into the hole, such that the graft lay on the posterior 
aspect of the tendon. The end of the construct was sutured to the supraspinatus 
tendon with 9-0 silk sutures. The deltoid and biceps muscle were closed using 7-
0 sutures and the skin was closed with staples. Animals were fed ad libitum and 
allowed full cage activity. Analgesic, Carprofen (5 mg/kg), was administered 
following induction of anesthesia and every 24 hours for 48 hours post-surgery. 
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Eight weeks following surgical repair of the tendon the animals were euthanized 
with sodium pentobarbital and both shoulders were removed for biomechanical 
and histological analyses. 
 
2.2.6 Biomechanical Testing 
Biomechanical testing was performed on freshly dissected supraspinatus 
tendons while still attached to the humerus. Prior to testing, the supraspinatus 
muscle belly was carefully removed from the supraspinatus tendon and the cross 
sectional area of the tendon was measured using a digital micrometer. To 
prevent the fracture of the humeral physis during mechanical testing, the 
humerus was potted with polymer into a custom-designed grip. The specimen 
was then placed into a Dynamic Mechanical Analyzer (RSA-III, TA Instruments) 
for uniaxial tensile testing. The end of the tendon was secured to a screw grip 
using sandpaper and cyanoacrylate. The specimen was attached to a 35 N load 
cell and aligned uniaxially. The specimen was loaded to failure at a rate of 0.3 
mm/sec or approximately 0.10/sec. Samples were tested at room temperature 
and were continuously moistened via a PBS drip throughout testing. The ultimate 
load-to-failure and location of failure (enthesis or tendon mid-substance) were 
recorded. The stiffness for each specimen was calculated from the linear region 
of the load-deformation curve. Statistical analysis was performed by two-way 
ANOVA with significance as P < 0.05. Data from the contralateral shoulders were 
combined for each injury group. Data are presented as mean ± standard error. 
 
2.2.7 Histomorphometric Analysis 
Following recovery, the supraspinatus tendon with the humerus still attached was 
carefully dissected from the surrounding tissue under a microscope leaving the 
supraspinatus muscle intact. Following dissection, samples were fixed in 10% 
neutral buffered formalin for 48 hours, decalcified in EDTA for 48 hours, and 
subsequently washed in phosphate-buffered saline solution. The samples were 
dehydrated and embedded in paraffin for sectioning. To facilitate comparisons 
between groups, an orientation of 90° between the humerus and supraspinatus 
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muscle was maintained for each sample during embedding. Serial sections 12-
µm thick, containing the repaired tendon and greater tuberosity of the humerus, 
were cut in the coronal plane and stained with picosirius red, safranin-O, and 
hematoxylin and eosin (H&E). Using an Olympus B light microscope, digital 
images of the stained slides were taken using a SPOT RT camera (Diagnostic 
Instruments, Sterling Heights, Michigan). Five representative slides for each stain 
and specimen were prepared. Each slide was evaluated using polarized and 
non-polarized light and analyzed by 3 different people. 
 
To evaluate collagen organization in the repaired tendon enthesis, sections 
stained with picrosirius red were imaged under monochromatic polarized light. 
The birefringence of collagen fibers was semi-quantitatively analyzed, based on 
brightness, to determine differences in collagen deposition and maturation at the 
site of repair 34,86. Five representative tissue sections across the full width of the 
tendon-bone interface were analyzed for each shoulder. The polarization plane 
was rotated until maximum brightness was obtained to account for variations in 
specimen orientation on the slide. Digital images were taken of each tissue 
section at X10 magnification during a single imaging session under identical 
imaging parameters. The images were imported into Image J software and 
underwent 8-bit digitalization. Non-collagenous material was shown as black 
(zero) and collagenous material was assigned a gray scale value from 1-255. 
Higher gray-scale values signify more organized and mature collagen. Using the 
Image J software, ten rectangular areas (50 x 50 µm) were randomly selected in 
the tendon directly adjacent to the tendon-bone interface. Mean gray scale 
values for each region were averaged for each specimen to obtain a brightness 
value. Statistical analysis of specimen brightness was performed by two-way 
ANOVA with P value < 0.05 considered significant. Data are presented as mean 
± standard error. 
  
The area of fibrocartilaginous material at the tendon-bone interface was 
assessed by use of safranin O stained sections. Safranin O stains sulfated 
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proteoglycans reddish-purple, a property referred to as metachromasia. Digital 
images of the stained sections were imported into Image J and areas of 
metachromasia were meticulously outlined and measured using the Image J 
software at a X4 magnification (National Institutes of Health, Bethesda, Maryland, 
USA). Measured areas were averaged for suture and construct repaired 
shoulders and contralateral controls. Statistical analysis of total area of 
fibrocartilage was performed by two-way ANOVA with P value < 0.05 considered 
significant. Data are presented as mean ± standard error. 
 
2.3 Results 
2.3.1 Gross Morphology 
At the time of necropsy, there was continuity between the tendon and bone in all 
acute and chronic repairs with no detectable differences between groups. All 
animals appeared healthy and showed no signs of infection. The cross-sectional 
area of the enthesis was measured and was not significantly different between 
each group in either acute or chronic injury repairs (3.4±0.8 mm2). 
 
2.3.2 Biomechanical Testing 
Minimums of 5 samples for each treatment group were tested uniaxially until 
failure. In the acute injury repair groups, four of the suture-repaired specimens 
(n=8) failed at the enthesis, while the rest of the suture-repaired specimens and 
all the construct-repaired specimens (n=5) failed at the tendon mid-substance. In 
the chronic injury repair group, three suture-repaired specimens (n=5) failed at 
the enthesis while the rest of the suture-repaired specimens and the entire 
construct repair group (n=5) failed at the tendon mid-substance. All non-operative 
contralateral shoulders failed at the tendon mid-substance during testing. 
 
Following 8 weeks recovery, acute and chronic injuries repaired with either 
suture or construct techniques displayed no differences in stiffness between 
groups. All repair groups were significantly less stiff than their respective contra-
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lateral shoulders and not significantly different from each other (Figure 2.3). The 
mean stiffness of the tendon-bone interface in the acute injury repair groups was 
as follows: contra-lateral (23.2±1.5 N/mm, n=13), suture repair (12.9±0.8 N/mm, 
n=8), and construct repair (14.0±0.7 N/mm, n=5). The suture and construct 
repaired shoulders achieved 56% and 60% of native contralateral stiffness 
respectively. The mean stiffness of the tendon-bone interface in the chronic injury 
repair groups was as follows: contra-lateral (21.7±1.2 N/mm, n=10), suture repair 
(9.3±1.6 N/mm, n=5), and construct repair (10.1±0.6 N/mm, n=5). The suture and 
construct repaired shoulders achieved 43% and 46% of native contralateral 
stiffness, respectively. 
 
The maximum load-to-failure was not significantly different between acute and 
chronic injuries repair with suture or tissue constructs. Each group was 
significantly less than its respective non-operative contralateral shoulder and not 
significantly different from the other group (Figure 2.3). The maximum load-to-
failure for acute injury repair was as follows: contra-lateral (25.0±1.7 N, n=13), 
suture repair (18.8±1.3 N, n=8), and construct repair (17.0±2.8 N, n=5). This 
corresponded to approximately 75% and 68% of the contralateral failure load for 
suture and construct repairs, respectively. Maximum load to failure for chronic 
injury repair groups was as follows: contra-lateral (22.9±1.4 N, n=10), suture 
repair (14.0±2.3 N, n=5), and construct repair (12.9±2.1 N, n=5), respectively. 
The suture and construct repaired shoulders achieved 61% and 56% of 
contralateral shoulder load to failure, respectively. 
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Figure 2.3 Mechanics of Tendon-Bone Interface Following Acute and Chronic Injury Repair 
A) Stiffness of contralateral (CL), suture repaired, and construct repaired shoulders and B) 
Load to Failure of contra-lateral (CL), suture repaired, and construct repaired shoulders. 
(#) Denotes statistical significance compared to CL shoulder (P<0.05). Data are shown as 
mean ± S.E. for each group. 
 
2.3.3 Histomorphometric Analysis 
Collagen birefringence was semi-quantitatively analyzed, based on brightness, to 
evaluate collagen organization at the tendon-bone interface. Five specimens 
were analyzed for each treatment group. Contralateral shoulders of acute and 
chronic injured shoulders were not significantly different and were combined for 
analysis. Suture and construct repaired shoulders, although significantly more 
disorganized (shown in picrosirius red staining) than contralateral shoulders, 
were not significantly different to each other in either acute or chronic injury 
groups (Figure 2.4). Additionally, although repaired chronic injuries trended 
towards lower gray scale values, no significant difference in collagen 
organization was observed between repaired acutely or chronically injured 
shoulders. Suture repairs of acute injuries had a mean brightness gray scale 
value of 70±1 gray scale units, while construct repairs had value of 70±4 gray 
scale units. Chronic injuries repaired with suture and construct techniques had 
gray scale values of 58±5 and 65±4 gray scale units, respectively. Non-operative 
contralateral shoulders had an average brightness value of 95±6 gray scale 
units. Representative images from each treatment and control group can be seen 
in Figure 2.5. 
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Figure 2.4 Collagen Organization at Enthesis Following Acute and Chronic Injury Repair. 
No significant differences were observed between acute and chronic injury groups. (#) 
Denotes statistical significance compared to contralateral (CL) shoulder (P<0.05). Data are 
shown as mean ± S.E. for each group. 
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Figure 2.5 Representative Collagen Organization of Enthesis A) Contralateral shoulder, B) 
Acute suture repair, C) Acute construct repair, D) Chronic suture repair, and E) Chronic 
construct repair. Images are of picrosirius red stained sections under polarized light and 
imaged at X40 magnification. 
A B 
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The area of new fibrocartilage formation was evaluated at the tendon-bone 
interface by determining the area of metachromasia of safranin O stained 
sections. Five specimens were analyzed for each treatment group. Contralateral 
shoulders of the acutely and chronically injured animals were not significantly 
different and were combined for analysis. The enthesis, following suture and 
construct repair of acute and chronic injuries, had significantly less fibrocartilage 
area than the native contralateral enthesis (Figure 2.6). No significant difference 
in area of fibrocartilage formation was observed in acute injury suture or 
construct repairs. The area of fibrocartilage formation in the chronic injury group 
was significantly less in suture repaired specimens compared to both construct 
repaired specimens and unrepaired, contra-lateral shoulders. The total area of 
metachromasia, or area of fibrocartilage, for each treatment group was as 
follows: contralateral shoulders (109,905±5,095 µm2), acute suture repairs 
(52,571±10,451 µm2), acute construct repairs (67,063±11,455 µm2), chronic 
suture repairs (11,272±6,707 µm2), and chronic construct repairs (40,432±7,600 
µm2) (Figure 2.6). Representative images from each treatment and control group 
can be seen in Figure 2.7. 
 
Figure 2.6 Fibrocartilage Formation at the Enthesis Following Acute and Chronic Injury 
Repair. Suture repair of chronically injured shoulders had significantly less fibrocartilage 
formation compared to both contralateral shoulder and construct repaired specimens. No 
significant differences were observed between acute and chronic injury groups. (#) 
Denotes statistical significance compared to contralateral (CL) shoulder (P<0.05). (##) 
Denotes statistical significance compared to acute suture repair (P<0.05). (###) Denotes 
statistical significance compared to chronic construct repair (P<0.05). Data are shown as 
mean ± S.E. for each group. 
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Figure 2.7 Representative Fibrocartilage Formation at Enthesis. Representative images of 
safranin O stained A) Contralateral, B) Acute Suture Repair, C) Acute Construct Repair, (D) 
Chronic Suture Repair, and E) Chronic Construct Repair sections. Area of metachromasia 
(depicted as red) in each image was outlined for semi quantitative analysis. Images are 
shown at X40 magnification. 
A B 
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H&E staining of the tendon-bone interface allowed for qualitative evaluation of 
the entheses repair. Acute and chronic tendon injuries repaired with suture had 
less area of fibrocartilage formation and fewer organized collagen fibers than 
both construct-repaired and contralateral shoulders. The attachment of tendon to 
bone utilizing our tissue constructs resembled a more organized, native 
appearance. Suture repaired shoulders in both acute and chronic injury models 
had a more abrupt, fibrous interface at tendon-bone transition site, especially in 
suture-repaired specimens of chronic injuries. Representative images from each 
treatment and control group can be seen in Figure 2.8. 
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Figure 2.8 Representative Structure at Enthesis. Representative images of H&E stained A) 
Contralateral, B) Acute Suture Repair, C) Acute Construct Repair, D) Chronic Suture 
Repair, and E) Chronic Construct Repair sections. Suture repaired shoulders were more 
disorganized and fibrous than contralateral or construct repaired shoulders. Images are 
shown at X40 magnification. 
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2.4 Discussion 
Tissue engineering to improve the architecture and structural integrity of the 
healing enthesis after rotator cuff repair offers future promise to improve 
outcomes in patients. Bone-like constructs, instead of tendon/ligament-like 
constructs, were used in this study based on their ability to specifically 
regenerate the tendon-bone interface in an ACL repair model. Future work 
involving the use of multi-phasic tissues (with both bone and tendon/ligament 
tissue) may further enhance the properties of the tendon mid-substance but was 
beyond the scope of this experiment. The objectives of this current study were to 
evaluate the efficacy of our scaffold-less tissue engineered tendon construct to 
regenerate the native tendon-bone interface of the supraspinatus following full-
thickness acute and chronic injury in a rat model. Furthermore, we tested the 
hypothesis that tendon-bone repair utilizing our scaffold-less construct could 
strengthen enthesis healing and improve collagen organization and fibrocartilage 
formation compared to suture fixation alone. 
 
In the acute injury repair model, our results demonstrate that there were positive 
effects with the utilization of our scaffold-less constructs. While no significant 
differences in structural mechanics were observed, failure occurred more 
frequently at the tendon-bone interface in suture-repaired, acutely injured 
shoulders. Histologically, qualitative differences in general morphology revealed 
more native histological architecture by 8 weeks post-operatively. In tendons with 
chronic injury, repairs utilizing our tissue engineered construct resulted in a more 
native-like enthesis. Despite similar biomechanical properties with load-to-failure 
testing, suture repaired specimens of chronic injuries failed more frequently at 
tendon-bone interface.  However, the structure of the construct repaired enthesis 
appeared qualitatively more native-like in appearance and quantitatively more 
fibrocartilage was observed at the tendon insertion site compared to suture 
repairs.  
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The formation of fibrocartilage at the tendon-bone insertion site has an important 
role in the force transmission and energy dissipation between two tissues with 
vastly different properties. This complex interface is seldom recreated with 
current fixation techniques and often results in repair failure. The healing of the 
enthesis following repair is known to be influenced by mechanical cues. In 
separate studies performed by Galatz and Hettrich et al., complete removal of 
load following repair via immobilization and botulinum toxin application to 
supraspinatus muscles resulted in decreased structural properties and 
decreased ECM production at the tendon-bone interface 54,77. As such, suture 
techniques that rely on rigid mechanical fixation of tendon to bone may impede 
signals that may be necessary for proper enthesis regeneration resulting in a 
more fibrous tissue interface. The unique ability of our initially compliant construct 
to sense and respond to local mechanical cues and biological factors has led to 
improved structure and fibrocartilage formation at the enthesis.  
 
The biological composition of our graft may also contribute to repair of tendon-
bone interface. Recent research has shown that application of MSCs, with the 
addition of appropriate growth factors, can enhance tendon-bone healing of the 
repair 70. Our constructs are fabricated from MSCs and driven towards an 
osteogenic lineage, via the addition of previously described growth factors. As 
such, enthesis regeneration at a repair site may be due to the unique cellular and 
molecular signals provided by the cells of our construct that are necessary for 
facilitating the proper host-mediated response. Alternately, the implanted 
construct may be actively forming a new interface tissue in vivo. Current studies 
are underway to evaluate the origin of the regenerated enthesis tissue.  
 
Although more successful at regenerating the enthesis than current suture 
techniques, the excessively high strains at the site of repair may have limited 
repair outcomes. High tensile loads, especially in chronically retracted tendons, 
can lead to elongation of the tendon, reducing overall muscle length and 
compromising shoulder function. Though the length of tendon following repair 
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was not evaluated in this study, gross morphological changes of the 
supraspinatus tendon and muscle were not observed. Nonetheless, due to the 
compliance of our tissue, the primary benefit of our construct may be initially 
biologic and a reliance on compositional properties of the graft until sufficient 
tissue mechanical development can occur. As such, initial load sharing at the 
repair site utilizing our construct as a biological in-lay may enhance repair 
outcomes.  
 
There were several limitations to this study. Mechanical testing evaluated 
stiffness and load-to-failure of a single test. Cyclic loading, a more clinically 
representative measure, was not performed. Furthermore, material properties 
utilizing tissue level strains of the repaired tissue were not evaluated due to 
technical difficulties and may explain the lack of significant differences in 
mechanics despite histological differences in tissue composition and location of 
failure. Assessment of the material properties of the regenerated tissue (i.e. 
moduli) utilizing tissue level strains, rather than only geometric properties 
(stiffness and load at failure) of the tissue, may better evaluate the quality of the 
regenerated tissue independent of size. Additionally, the creation of a chronic 
supraspinatus injury in the rat may not be fully representative of the human 
condition. Healing in the rodent model is relatively robust and may not simulate 
the difficulties experienced in structure failure after large and massive repairs in 
human patients. Additionally, as this study focused specifically on enthesis 
regeneration, important components of rotator cuff injury specific to the tendon 
mid-substance and muscle such as muscle atrophy, fatty infiltration, quality of 
tendon, etc., were not evaluated. 
 
In conclusion, repair of acute supraspinatus injuries in a rat model with 
engineered constructs more accurately recapitulated the appearance of the 
native enthesis but was not significantly different biomechanically compared to 
suture techniques. Utilization of scaffold-less constructs for repair of chronic 
rotator cuff injuries was found to reduce scar formation and increase the area of 
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fibrocartilage formation at the tendon-bone interface over suture-only repairs. 
Further investigation is needed to optimize the ideal tissue properties and 
surgical technique for encouraging maximum enthesis regeneration in vivo. 
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Chapter 3  
Standardization of Existing Methodologies for 
Reproducible Construct Fabrication 
3.1 Introduction 
The previous chapter evaluated the use of scaffold-less tissue constructs for 
regeneration of the native tendon-bone interface following acute and chronic 
rotator cuff injury and repair. As with rotator cuff repair procedures, current ACL 
repair procedures also often fail to regenerate the native fibrocartilaginous 
enthesis and have been implicated in poor long-term outcomes and pre-mature 
graft failures. However, unlike repairs of the supraspinatus tendon that require re-
attachment of the damaged tissue to its original insertion site, current strategies 
to repair the ACL replace the entire ACL complex within the knee. Current ACL 
replacement grafts are secured to bone tunnels drilled through the femur and 
tibia using interference screws, span the intra-articular space, and provide 
immediate knee stability. These ACL replacement grafts from cadaveric allografts 
or autografts from the patient’s patellar tendon or hamstrings tendon have 
several disadvantages. The grafts often do not fully integrate with the native 
tissue within bone tunnel and fail to restore full function to the knee. Additionally, 
a mismatch of mechanical properties exists between the tendon replacement 
graft and the native ACL 105.  This mismatch of mechanical properties may play a 
role in the early onset of OA.  As such, a multi-phasic graft capable of integrating 
with both bone tunnels and regenerating the native properties of the ligament 
mid-substance would be advantageous. 
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As described in Chapter 1, our lab has tissue engineered a compliant BLB graft 
consisting of viable ligamentous mid-substance tissue, osteogenic tissue at each 
end, and viable entheses in between. In both rat MCL and sheep ACL repair 
models the graft induces endogenous bone and ligament regeneration, rapidly 
develops biochemically relevant and biomechanically compatible interfaces with 
native tissue, and restores the native anatomy and function to the knee 105. As an 
“off-the-shelf” allogeneic ACL graft, our tissue-engineered graft could eliminate 
donor site morbidity from autologous tendon harvesting and improve the 
structural and mechanical outcomes compared to current grafting techniques105.  
It is clear that utilization of this tissue engineering approach has tremendous 
potential to improve musculoskeletal tissue repair and regeneration.  
 
A significant amount of work remains before we can use our current lab-based 
tissue engineering processes for large-scale clinical use. Our hands-on, labor 
intensive laboratory methods must be advanced to more efficient protocols 
capable of producing consistently uniform, reproducible constructs that meet the 
current industry regulations within the health care field. The commercialization of 
our BLB construct, specifically for ACL repair, will be used for the remainder of 
this thesis as an application-specific model for the translational process of tissue 
engineering products. 
 
3.2 Background/Motivation 
The Food and Drug Administration (FDA) regulates all engineered tissue and 
regenerative medicine products. The FDA oversees the pre-market approvals 
and conducts post-market surveillance of existing products. The focus of the FDA 
is to ensure the safety and effectiveness of new products through clinical trials 
and to oversee the manufacturer’s processes validation in accordance with 
current good manufacturing practice (CGMP) regulations. Overall these 
regulations require exquisite definition and control of the product and fabrication 
process 177. 
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Failure to adequately transition from a labor-intensive laboratory process 
performed by expert technicians to an automated industrialized production 
method is a major hurdle in the translation of all current tissue engineering 
technologies. Though process validation may be performed in parallel with 
clinical trials, the consideration of designing a process that is compliant with 
existing FDA regulations is essential to avoiding late-stage product failures and 
costly product development cycles. Implementing FDA compliant technologies 
early in the research stage has the potential to shorten the duration of the FDA 
approval process and hasten the availability of our tissue-engineered grafts for 
widespread clinical use. 
 
Tissue engineering products, in particular, are among the most complex products 
to manufacture132. Tissues are composed of various living cells and ECM 
components that are constantly changing and remodeling in response to 
environmental cues. Due to the inherent heterogeneity of cells, the FDA requires 
creation of tissue end product specifications and the demonstration of a 
consistent manufacturing process. As such, extensive work in the tissue 
engineering/regenerative medicine field is needed to design and implement 
novel, high-quality manufacturing systems capable of generating sufficient 
amounts of data needed to establish statistical confidences of variability, define 
product specifications, and demonstrate overall process consistency. 
 
CGMP requires that each step of the manufacturing process be designed and 
confirmed such that in-process materials and the final-end product(s) are 
produced consistently and reliably, and meet their predetermined quality 
attributes. The manufacturer must evaluate the process performance and control 
batch-to-batch variability within the system. To ensure process consistency, in-
process specifications must be established to monitor variability in the 
characteristics of process materials or end products. As described by CGMP 
regulations, “in-process specifications shall be derived from previous acceptable 
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process averages and process variability estimates where possible and 
determined by the application of suitable statistical procedures where 
appropriate” (See FDA Section 2.11.110(b)). 
 
Therefore, as a first step for our technology, a robust, well-established 
manufacturing method must be designed at an early stage to provide information 
and knowledge about product reproducibility and to define the process to identify 
and control for variability. To eliminate or reduce the variability associated with 
our multi-step process, critical steps reliant on technician skill should be 
minimized or eliminated. In addition, the ability to systematically collect data 
during the process is critical to establishing baseline averages, to evaluating the 
sources, degree, and impact that procedural variation has on manufacturing 
process, and ultimately to determining the attributes of the end product. Only 
after process variability has been minimized, controlled, and properly 
characterized can in-process specifications be defined minimizing any remaining 
variation in proportion to the risk it represents to the process and final product. 
Once appropriate controls have been established, the process can be evaluated 
under CGMP compliant conditions to demonstrate that the commercial 
manufacturing process is capable of consistently producing a quality product. 
Additionally, from a manufacturing standpoint, understanding the process 
variation can lead to more efficient manufacturing systems that improve 
production volumes and reduce failure rates.  
 
The process of obtaining FDA approval for products in the field of tissue 
engineering regenerative medicine is complex and the specific requirements for 
process validation and regulatory approval are not clearly defined. Due to the 
broad range of medical technologies being developed, new products are 
generally evaluated on a case-by-case basis. Thus, the specific information that 
is needed as part of an FDA regulatory submission to demonstrate sufficient 
process control is unknown. Guidance documents provided by the FDA outline 
the FDA’s current thinking on various topics (including process validation) and 
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serve as useful guidelines for industry. These documents incorporate principles 
and approaches that manufacturers can use to validate manufacturing processes 
for human, animal, drug, or biological products under current CGMP regulations. 
 
3.2.1 Current BLB Manufacturing Process 
For the purposes of this study, I will focus exclusively on the fabrication of the 
ligament portion of our BLB construct, the region that replaces the damaged ACL 
tissue within the intra-articular space. The stiffness of this region directly 
determines the graft’s ability to accommodate strain under normal knee loading 
and the fabrication of this region is currently the most difficult aspect of the BLB 
fabrication process to reproduce. Thus, the goal of this study is to design 
strategies to enhance construct production and to characterize the properties of 
the ligament region during fabrication. The methods developed here to establish 
a reproducible protocol for production of the ligament-region of the BLB graft will 
be useful as a guide for improving production of the bone-region in future 
research. 
The original process used for BLB fabrication has been described by Ma et al., 
with slight modifications 104,105. Briefly, the methods used in the Ma paper to 
harvest bone marrow for the fabrication of ligament tissue required the sacrifice 
of a donor animal, removal of the whole femoral bone, and extraction of the 
entire content of femoral bone marrow. Obviously, the removal of the entire 
femur and the extraction of the entire marrow contents is not a practical method 
for obtaining cellular material and should be replaced with more clinically relevant 
bone marrow aspiration techniques. In the previous fabrication process, the 
entire amount of extracted marrow was plated onto four polystyrene dishes and 
MSCs were isolated by their plastic adherence properties. This method of bone 
marrow extraction led to low primary MSC yields and often necessitated 
significant and unpredictable amounts of time in culture to achieve suitable cell 
quantities for passaging. The execution of these process steps at irregular 
intervals added an unnecessary variable to the protocol and reduced the overall 
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efficiency of the process. The previous methodology resulted in differences in the 
amount, cellularity, and composition of bone marrow collected for tissue 
fabrication. Standardization of the original isolation procedure was needed to 
appropriately evaluate variability between and within donor samples and recover 
reliable cell volumes at defined time points. 
In addition to standardizing the bone marrow isolation methods, the MSC 
differentiation and expansion methods associated with our original BLB protocol 
also required improvement to obtain sufficient quantities of a consistent starting 
cell population prior to seeding. Existing methodologies induced an unknown 
amount of MSCs toward a fibrogenic lineage and passaged these cells every 
other day at a 1:3 liquid volume ratio until sufficient numbers of ligament cells 
were achieved. Failure to rigorously monitor the plate density to the desired 80% 
confluence mark between passages led to significant variability in the number of 
recovered cells. This error in cell number was exacerbated in successive 
passages. The recovery of low cell quantities during passaging led to a decrease 
in the number of constructs that could be fabricated, and reduced the overall 
efficiency of the process. Optimal culture conditions for passaging MSCs typically 
occur at 80% confluency 115. High cell densities during passaging were typically 
indicative of a plate that was well beyond 80% confluence. The resultant cell-cell 
contact at these high cell densities may lead to changes in cell phenotype, 
genetics, and construct structure and function that can introduce significant 
variability into the manufacturing process. Thus, we determined that it was 
imperative to standardize the methodologies used to expand and induce the 
MSCs to ligament cells during passaging and to maintain the cells at each 
passage as close to 80% confluence as possible, to minimize cell-to-cell contact 
and provide adequate cell qualities for tissue fabrication. The establishment of 
set passage densities would allow for accurate predictions of appropriate times 
between passages necessary to obtain consistent starting cell numbers.  
In addition to the issues associated with obtaining and expanding the MSC 
population to a consistent fibrogenic lineage, we recognized that our current 
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methodologies for fabricating 3D BLB constructs could also be improved. The 
process for capturing and constraining the spontaneously delaminating ligament 
monolayers into uniform cylindrical constructs, in particular, was unpredictable, 
technically challenging, led to a significant loss of constructs, and reduced the 
overall number of constructs produced. Briefly, in our original method, once a 
hyper-confluent monolayer was formed and a sufficient amount of extracellular 
matrix was produced, plates were switched to a low-serum medium and fed TGF-
β to induce intercellular tension and spontaneous contraction of the monolayer. 
These resulted in the spontaneous delamination of the monolayer that facilitates 
the formation of a 3D cylindrical construct. During delamination, the monolayer 
had to be delicately transferred onto a syglard-coated plate and pinned. 
Constraint pins were applied to the monolayer and the delaminating tissue 
aligned along a singular axis of the pins allowing for the remodeling of the 
construct into a 3-D tissue (Figure 3.1). 
The delamination process occurs spontaneously. The inability to continuously 
monitor and manipulate the tissue at the beginning of the delamination process 
led to the loss of a significant number of constructs. Failure to constrain the 
monolayers at an appropriate length before significant tissue contraction 
occurred resulted in tissues of an unsuitable length for use as a replacement 
graft  (>6cm) (Figure 3.1). Additionally, variation in the placement of the pins 
often led to uneven tension during tissue contraction and resulted in construct 
thinning, abnormal construct geometry, and eventual failure in a substantial 
number of constructs (Figure 3.1). 
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Figure 3.1 In vitro Tissue Constructs A) BLB graft pinned at an appropriate length for use 
in ACL reconstruction. Suture integrated into the bone regions (ends) of the construct is 
applied immediately prior to surgery to introduce and anchor the construct within the 
knee. B) Ligament constructs manually formed. Variability in pin placement resulted in 
varied construct lengths and geometries rendering the tissue unsuitable for ACL 
reconstruction. 
Our previously published data on the biological and mechanical properties of the 
BLB were of a relatively low sample size (n=3) and were derived from cells of a 
single donor animal.  Thus, we have been unable to report the consistency and 
reproducibility of the fabrication process within and between multiple donor cell 
populations. Additionally, the meticulous and user-dependent steps of our 
construct formation process led to relatively few appropriately formed constructs 
suitable for implantation or in vitro evaluation. This overshadowing technician 
variability prevented the evaluation of construct variability with respect to size, 
mechanics, and histology, within and among different donor lots. Thus the 
second objective of this study was to design a novel tissue capture system to 
facilitate 3D construct delamination without technician manipulation. 
3.3 Objective 
The objective of this study was two-fold. First, a standardized bone marrow (BM) 
isolation technique and a reliable method for obtaining and expanding MSCs 
towards a fibrogenic lineage were needed. Second, following the production of a 
consistent cell population, a novel tissue capture system was needed to 
automate the capture and 3D formation of the construct. To complete these 
objectives, the old BLB fabrication process described above was changed to 
incorporate: Ficoll MSC cell isolation method to produce a well-defined starting 
1cm 
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cell material from a clinically relevant bone-marrow aspiration, consistent 
passage densities to limit significant cell-cell contact known to alter cell 
phenotype and function, and a novel capture system to automatically capture the 
monolayer delamination and allow the formation of a 3D construct on the plate. 
We hypothesized that the incorporation of these changes would allow for the 
fabrication of more consistent and reproducible tissue constructs with defined 
end-product specifications and marginal variability. The information and 
knowledge gained from the addition of these methodologies will be useful in 
generating the large number of constructs needed to establish an acceptable 
baseline average and to statistically evaluate the process variation. 
3.4 Methods 
3.4.1 Preparation of Solutions and Media 
We did not perceive the media and growth factors to be a significant source of 
variation in the fabrication process. Solutions used for cell processing were 
prepared as described in previous published work, with slight modifications 
104,153. Briefly, all media and solutions were prepared and stored at 4°C prior to 
use. Media were warmed in a heated water bath to 37°C before use for the 
culture of cells. Media were prepared, as described previously, with slight 
modifications 104,153. Growth medium (GM) consisted of Dulbecco’s Modified 
Eagle Medium (DMEM; Gibco, Rockville, MD, Cat# 10565-042) supplemented 
with 20% Fetal Bovine Serum (FBS; Gibco, Rockville, MD, Cat# 10437-028) and 
2% antibiotic-antimycotic (Sigma, St. Louis, MO, Cat# A9909). Fibrogenic GM 
consisted of GM supplemented with only 600ng/ml bFGF, 0.13 mg/ml ascorbic 
acid-2 phosphate and 0.05 mg/ml L-proline. Differentiation medium (DM) 
consisted of DMEM supplemented with 7% Horse Serum Albumin (HS, Gibco, 
Rockville, MD, Cat# 16050-122) and 2% antibiotic-antimycotic. Fibrogenic DM 
consisted of DM, plus the addition of 0.13 mg/ml ascorbic acid-2 phosphate, 0.05 
mg/ml L-proline, and 2 ng/ml transforming growth factor-beta (TGF-b; Peprotech, 
Rocky Hill, NJ, Cat# 100-21).  
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3.4.2 Preparation of a Novel Plate to Eliminate the Loss of Monolayers 
To reduce the loss of monolayers during the delamination process, we fabricated 
a novel tissue culture plate designed to automatically capture the monolayers 
during delamination. This eliminated the need for time-consuming observation of 
monolayers and labor-intensive manual pinning of the plates. To accomplish this 
task we drilled two small holes (0.53 mm) through the culture surfaces of 100 mm 
tissue culture treated polystyrene plates (BD Falcon). Each hole was drilled 3 cm 
from the center of the plate and aligned axially. Stainless steel wire, 0.51 mm in 
diameter, was cut to approximately 1 cm in length. The wire pieces were bent at 
right angles approximately 6.35 mm from one end. The unbent ends of the pins 
were inserted into the drilled holes of the tissue culture plate until the bent end 
was flush with the exterior base of the plate. Using a silicone elastomer (Sylgard-
102, McMaster-Carr), the pins were sealed in place between the base of the 
culture plate and an additional polystyrene lid that prevented leakage or damage 
during use. The elastomer was allowed to cure for at least 12 hours in an oven at 
37°C. The end result was a tissue culture plate with two steel pins protruding 
from the culture surface 60 mm apart, termed a “pin plate” (Figure 3.2). The pin 
plates were disinfected with 70% EtOH, and UV treated (UV wavelength 253.7 
nm) for at least 1 hour prior to use. The same fabrication methodology can easily 
be applied to tissue culture plates of various sizes. Plates 35, 60, and 150 mm in 
diameter could be fabricated with posts placed 1.5 cm, 2 cm, and 6 cm apart, 
respectively. Before the addition of cells, the plates were again sprayed with 70% 
EtOH, placed into a sterilized laminar flow hood, and rinsed with DPBS. 
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Figure 3.2 Novel “Pin Plate” Capture System. Shown polystyrene tissue culture dish is 100 
mm in diameter. Distance between pins is 60 mm. 
 
3.4.3 Bone Marrow Aspiration and Isolation Technique 
To shift to a more clinically relevant method for obtaining MSCs, bone marrow 
was aspirated from the iliac crest of sheep using a Monoject Illinois needle 
(Sherwood Medical Company, St. Louis, Mo).   With the animal under general 
anesthesia induced by intravenous propofol and sustained with inhalation of 
isoflurane in oxygen, bone marrow aspirates were collected using heparinized 
needles and dispensed into EDTA blood collection tubes (BD, San Jose, Ca) for 
processing. The marrow was passed through a 100 µm filter to remove solid 
debris before it was consolidated into a single 50 ml conical. An equivalent 
volume of DPBS was added to the bone marrow. Next, the diluted bone marrow 
solution was slowly added to a 15 ml layer of Ficoll-Paque™ Premium (GE 
Healthcare, Munich, Germany) contained within a separate conical and 
centrifuged (AccuSpin FR; Beckman Coulter Inc., Fullerton, CA) at 600 g for 30 
minutes @ 25°C. Following centrifugation, the upper layer of the mixture 
containing plasma and platelets was discarded and the mononuclear cell (MNC) 
layer, containing the resident MSC population, was transferred into a new sterile 
conical. The cells were suspended in at least three times volume of DPBS and 
centrifuged at 500 g for 10 minutes. The supernatant was removed and an 
equivalent volume of ACK lysis buffer was added to the pellet volume to lyse any 
remaining red blood cells. The conical was then filled with DPBS and centrifuged 
at 400 g for 5 min. The supernatant was again removed and the MSC pellet was 
re-suspended in 20 ml of GM. Viable cells were counted via trypan blue 
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(Invitrogen) exclusion staining and a Countess automated cell-counting system 
(GE Healthcare). Viable cells were immediately plated at a 40,000 cells/cm2 
density to approximate the original protocol (approximately 80% plate confluency 
within 5-15 days). 
 
3.4.4 Optimization and Standardization of a Protocol for the Expansion of MSCs 
To optimize and standardize the methods for MSC cell expansion, the following 
protocol was established. First, the adherent MSC population was allowed to 
attach for 3 days before the plate was rinsed with DPBS to remove any 
remaining debris or contaminating non-adherent cell populations.  Next, MSCs 
were induced towards a fibrogenic lineage and expanded to sufficient numbers 
by feeding fresh GM supplemented with 600 ng/ml bFGF every 2 days. Eight 
days after plating plate were approximately 50-80% confluent and the plate-
adherent cell population was passaged.  
 
Approximately 12 µl/cm2 of trypsin-0.25% EDTA was added to the culture plate 
surface before the culture plate was placed into a tissue culture incubator at 
37°C, 5% CO2, and 95% humidity for 10 minutes. The trypsin was neutralized by 
the addition of GM comprised of 20% FBS. The cell suspension was removed 
from the tissue culture plate and centrifuged at a speed of 1500 rpm for 5 min. 
Following centrifugation, the supernatant was removed and the viable cells were 
counted in triplicate via trypan dye exclusion using a Countess automated cell 
counter. Cells were re-plated at a density of 5,000, 10,000, and 20,000 cells/cm2 
and passaged approximately every 48 hours to achieve the ideal plate 
confluency (80%) for successive passaging and minimizing cell-to-cell contact. At 
passage three, cells were collected and used for construct fabrication. Statistical 
analysis of recovered cell yields was performed with a one-way ANOVA and 
P<0.05 considered significant. Bartlett's test with P<0.05 was used to evaluate 
the equality of variances between groups.  
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3.4.5 Formation of Ligament Constructs 
The protocol for the formation of the 3-D ligament tissue was not altered from 
previously published papers 105. Briefly, cells were seeded onto 100 mm 
polystyrene pin plates at a density of 21,000 cells/cm2. Fibrogenic GM was 
exchanged every other day for 8 days until a confluent monolayer was formed. At 
that time, the medium was replaced with fibrogenic DM and cultured another 5 
days until spontaneous delamination occurred. The plates were kept in a tissue 
culture incubator at 37°C, 5% CO2, and 95% humidity and DM was exchanged 
every 2 days. Following delamination, the tissues were maintained in fibrogenic 
DM and allowed to mature between the constraint pins for 2 weeks before 
analysis. Partially delaminated constructs were manually rolled upon pin plates to 
maintain consistent time in culture prior to mechanical and histological testing. 
 
3.4.6 Mechanical Analysis 
Mechanical testing of the tissue-engineered constructs was performed with a 
custom-built tensile testing system with a 2.5 N load cell (Applied Biosystems). 
Constructs were manually removed from pin plates and submerged in a warmed 
DPBS bath within the testing system. Construct ends were secured to the 
apparatus using two custom designed Velcro compression grips. The grips were 
incrementally lengthened to approximate the original length of the construct upon 
the pins of the culture dish. Sixty-micron diameter beads were painted onto the 
surface of the tissue for post analysis digital image correlation (DIC) to 
extrapolate the tissue-level strain during testing. The construct was loaded until 
failure occurred at a rate of 0.01/sec. Synchronized force and image recordings 
were complied from a Basler A102fc digital video camera using LabVIEW. 
 
Cross-sectional area measurements were extracted from a microscope image 
captured immediately prior to loading. The image was imported into Image J and 
pixels calibrated to scale. Vertical lines were drawn at 10 randomly chosen 
regions along the length of the construct to account for sampling variation of the 
construct’s diameter (Figure 3.3). Approximating the construct as a cylinder, the 
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cross-sectional area was determined and utilized for calculations of stress and 
subsequent data analysis. Statistical analysis of average construct diameters 
was performed via one-way ANOVA test with a P<0.05 considered significant. A 
Bartlett's test with P<0.05 was used to evaluate equality of variances between 
groups. 
 
 
Figure 3.3 Determination of Construct Diameter. Image depicts the technique used for 
determination of construct diameter during mechanical testing. Lengths of 10 randomly 
spaced vertical lines were determined for each specimen tested. 
 
Metamorph software was used for DIC and tracking. The tangent modulus over a 
strain range of 0.05-0.07 was determined by calculating the secondary slope of 
the nominal stress (load/cross-sectional area) versus nominal strain (change in 
separation of image data/ initial separation) response curve. Statistical analysis 
was performed via one-way ANOVA with P<0.05 considered significant. A 
Bartlett's test with P<0.05 was used to evaluate equality of variances between 
groups. 
 
3.4.7 Histological Analysis 
The constructs used for histological analyses were immediately fixed in 4% 
paraformaldehyde (PFA) for 1 hour while secured to pin plates. The fixative was 
replaced with a 15% sucrose solution for 1 hour at 4°C followed by a 30% 
sucrose solution overnight (>12 hrs). The constructs were then transferred into 
TBS medium, frozen over dry ice, and stored at -80°C until needed. Samples 
were sectioned with a cryostat to obtain 12 µm longitudinal sections that were 
adhered to Superfrost Plus microscopy slides until used for staining. The general 
morphology of the tissue sections was analyzed with H&E staining. Picrosirius 
red staining under polarized light was used to detect collagen birefringence within 
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the sections. Birefringence under identical imaging parameters is indicative of 
collagen alignment. All tissue sections were imaged at x10 magnification using 
an inverted light microscope (Nikon 23500). 
 
Immunofluorescent staining with specific antibodies was performed to detect the 
presence of collagen type I within the engineered tissues. Frozen sections were 
fixed with ice-cold methanol for 10 min and subsequently rinsed 3 times with 
Phosphate Buffered Saline (PBS). Sections were blocked for 30 min with PBS-
0.05% Tween20 (PBST) containing 20% calf serum (PBST-S) at room 
temperature. Sections were incubated overnight at 4°C with the primary 
antibodies in PBST-S. The concentration of rabbit anti-rat collagen type 1 
(Abcam) was 10 mg/ml. Sections were incubated at room temperature for one 
hour with Cy3-conjugated anti-mouse or anti-rabbit antibody (Jackson 
ImmunoResearch Lab., West Grove, PA). Nuclei were stained incubation with a 
DAPI solution (Sigma, St. Louis, MO) in PBST for 5 min. The sections were 
examined and photographed with a confocal microscope (Olympus A) with dual 
excitation wavelengths of 488 nm and 568 nm. 
 
3.5 Results 
3.5.1 Bone Marrow Aspiration and Isolation Technique 
To standardize the collection and isolation of our initial MSC population, a Ficoll 
density centrifugation technique was used to isolate the mononuclear cell fraction 
from a clinically relevant bone marrow aspiration harvested from the iliac crest of 
sheep. Comparative analyses of cell yields (cells/cm2) isolated from four different 
BM donors are shown in Table 1. The plastic adherent MSCs were recovered 
following 8 days in culture. The coefficient of variance (standard deviation/mean) 
of MNCs and recovered MSCs was 28% and 74%, respectively. The relatively 
high variability between donors observed among MSCs recovered following 8 
days in culture, suggested differences in BM composition or MSC growth. Cells 
isolated from donors 2-4 visually appeared less than 80% confluent during 
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passaging while the MSCs recovered from donor 1 were approximately 85% 
confluent at equivalent time points. Nonetheless, MSCs recovered from each 
donor were subsequently expanded and used for construct fabrication as 
described above. 
 
Table 1 Comparative Analysis of MSC Yields 
Donor # Sex BM Aspiration Volume (ml) MNC Cells 
MNC Yield 
(cells/ml BM) 
Seeding 
Density 
(cells/cm2) 
MSC Yield 
(cells/cm2) 
1 F 10.0 1.1E08 1.1E07 4.0E04 4.4E04 
2 F 30.0 2.2E08 7.2E06 4.0E04 9.5E03 
3 F 7.0 5.1E07 7.3E06 4.0E04 2.5E04 
4 F 14.0 8.3E07 6.0E06 4.0E04 9.7E03 
Average N/A 15.3 1.2E08 7.9E06 N/A 2.2E04 
S.D. N/A 10.2 7.1E07 2.2E06 N/A 1.7E04 
C.V. N/A 67% 62% 28% N/A 74% 
 
3.5.2 Expansion of MSCs with Standardized Passage Densities 
The ability of MSCs cultured in fibrogenic media to form 3D constructs following 
expansion at various passage densities (5,000, 10,000, and 20,000 cells/cm2) 
was evaluated. The confluency of the plates and number of viable cells 
recovered at each passage was recorded. Cells were utilized for construct 
formation following passage 3. Representative images of each plating density 
immediately prior to passaging are shown in Figure 3.4. Passaging at 5,000 
cells/cm2 yielded approximately 80% plate confluence every other day with 
minimal contact between cells. Passaging at densities of 10,000 cells/cm2 and 
20,000 cells/cm2 resulted in plates approximately 90% and 100% confluent at 
equivalent time points.  
 
Following passage 3, the cells from each group were seeded onto polystyrene 
tissue culture dishes at a plating density of 21,000 cells/cm2. At this plating 
density, cells achieved 100% confluence within 2 days with a hyper-confluent 
monolayer observed following 8 days in culture (Figure 3.4). Monolayers 
successfully delaminated by day 15 of the fabrication protocol. As no apparent 
differences in the cells’ ability to form a 3D construct were observed among cells 
passage at different densities, the 5,000 cells/cm2 passage density was utilized 
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for all future experiments.  This density maximized the potential cell yields and 
established a consistent cell expansion protocol for construct formation. 
 
Figure 3.4 Average Cell Yield and Plate Confluence. A-C) Average cell yield/cm2 and 
representative confluence at 5k, 10k, and 20k cells/cm2 passage densities, and D) Plate 
confluence following plating and 8 days of culture. 
 
3.5.3 Reproducibility of MSC Expansion Protocol 
Cells isolated from each of the four donors, as described in 3.5.1, were seeded 
onto 150 mm tissue culture plates, passaged at a 5k cells/cm2 density every 48 
hours, and fed GM supplemented with 600 ng/ml FGF-b. Averaged cell 
yields/cm2 from all donors, at each passage, were recorded as mean ± S.E. and 
shown in Figure 3.5. Representative plate confluences described in Figure 3.4 
are plotted for each passage in Figure 3.5. Plates did not exceed 80% 
confluence at any passage time point, but the cell density was greatest following 
passage 2. Recovered cells at each passage were not significantly different 
between donors. The relative variability (standard deviation/mean) of cell yields 
at each passage, for each donor, was approximately 34±14% indicating a 
moderate level of variability between donor groups. 
 
Figure 3.5 Cell Yield Following Passaging. Data represents average cell yield/cm2 ± S.E. 
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3.5.4 Fabrication of Ligament Constructs Utilizing Standardized BLB Protocol 
Having standardized the seeding and passage densities optimal for expansion, 
MSCs from each of the four donors were seeded onto the custom 100 mm pin 
plates and cultured in fibrogenic GM for 8 days until a confluent ligament 
monolayer was formed. The GM was then replaced with DM and the monolayer 
was cultured for an additional 5 days. The constructs began to spontaneously 
self-delaminate approximately 4-5 days following the switch to DM, or 13 days 
from the initial plating of MSCs. The delaminating monolayer was captured on 
the posts of the pin-plates and created a uniform 3D ligament construct 6 cm in 
length (Figure 3.6A). The constructs were allowed to condense and mature on 
the posts for 2 weeks and formed a uniform construct diameter of approximately 
0.9±0.1 mm (mean ± S.D.). Average construct diameters for each donor, 
determined from images taken during mechanical testing, are shown in Figure 
3.6B. No significant differences in average construct diameter were observed 
between donors. Additionally the standard deviation within each group was not 
significantly different among groups. The average coefficient of variation for 
construct diameters within each batch of constructs was 16±4% and not 
significantly different between donors indicating that the construct diameters 
were uniform and reproducible within and between donor groups. 
 
Figure 3.6 Ligament Construct Formation A) Construct captured via pin plate at 1-week 
post-delamination and B) Construct diameter 2 weeks following delamination. Data are 
represented as mean ± S.E. for each donor. 
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3.5.5 Mechanical Analysis of Constructs 
Following measures of diameter, the mechanical properties of the constructs 
were determined from a minimum of 6 samples. Overall, constructs had average 
tangent moduli of 2.3±1.1 MPa within a physiologic strain range of 0.05-0.07. The 
tangent moduli (shown as mean ± S.D.) of the constructs fabricated from each 
respective donor are shown in Figure 3.7. The average coefficient of variation 
within each batch of constructs was 26±6% and was not statistically different 
among donors. The relative variability of the tangent modulus among all donors 
was relatively high (50%) and likely attributable to the mechanical properties of 
constructs fabricated from donor 1 cells. The tangent moduli of the constructs 
fabricated from cells of donor 1 were significantly stiffer (about two-fold greater) 
than constructs engineered from cells obtained from the other three donors. 
Significant differences in tangent moduli were not observed between constructs 
fabricated from donors 2, 3, and 4.  
 
Figure 3.7 Construct Mechanics. Data are presented as mean ± standard error. (#) denotes 
significance compared to donor 1. 
 
3.5.6 Construct Histology 
Following mechanical testing, the constructs were frozen and saved for 
histological analysis of tissue properties. Representative images of constructs 
fabricated from each donor are shown in Figure 3.8. H&E staining for general 
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relatively amorphous tissue in the center. Increased birefringence of collagen 
tissue was observed using picrosirius red staining and polarized imaging 
methods and suggests an increase in collagen fiber alignment in donor 1 
constructs versus constructs of other donor groups. Antibody staining of type 1 
collagen and DAPI showed that the ECMs of all donor constructs were 
comprised of primarily type 1 collagen and contained viable nuclei throughout. 
Tissue compositions and structures from this study were comparable to previous 
published works evaluating morphology of engineered ligament constructs. 
 
Figure 3.8 Histological Staining of Ligament Constructs Top Row: H&E of general 
morphology for all respective donors, Middle Row: Picrosirius Red staining imaged under 
polarized light (yellow/red). More collagen alignment was present in constructs from 
Donor 1. Bottom Row: Collagen type 1 (red) /DAPI (blue) immunostaining. All images were 
taken at X40 magnification. Scale bar = 200 µm. 
 
3.6 Discussion 
The overall goal of this study was to implement a standardized process to 
fabricate reproducible and uniform tissue constructs. Creation of such a process 
is critical for evaluating manufacturing consistency and for identifying and 
controlling sources of variation within the manufacturing system. The utilization of 
a non-terminal bone marrow aspiration method and Ficoll density gradient 
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isolation technique allowed for a consistent number of plastic-adherent MSCs to 
be isolated from a known amount of starting material. Additionally, considering 
multiple aspirations can be performed from a single donor, these methodologies 
greatly improve the amount of cells and the number of resultant constructs that 
can be fabricated from a given BM donation.  
 
As the new BLB fabrication method can be performed from a routine bone 
marrow aspiration, commercial manufacturing can be performed as an 
autologous or allogeneic process. An autogenic manufacturing process would 
treat each graft as a patient-specific product. While the risk of immune rejection 
is eliminated with autogenic grafting, the variation between the starting cell 
sources obtained from patient specific bone marrow aspirations can lead to large 
variations in the tissue-engineered end products and make it difficult to meet the 
established manufacturing process controls and end-product specifications 
necessary to demonstrate the end products are acceptable for use. In contrast, 
an allogeneic process, while having some risk of immune rejection, would allow 
for many constructs to be made from a single well-characterized donor source 
and is a more commercially viable approach for manufacturing our grafts. 
 
Although the use of the Ficoll isolation technique improved upon our existing 
methodology by providing an increased number of adherent MSCs, significant 
variability still existed in the resultant cell isolates from each donor. Despite each 
plate having an equivalent numbers of mononuclear cells seeded initially onto the 
cell culture plates (40,000 cells/cm2), the cell yields following 8 days of culture 
were significantly different. This finding is consistent with the work of other 
researchers that have demonstrated variability in MSC yields even between two 
aspirations taken from the same donor during the same procedure 28. This finding 
suggests that the initial plating density may not be critical for isolating a well-
defined cell population119 and that amplification of cells with successive passages 
may be sufficient to expand and isolate a purified MSC source. However, even if 
a purified MSC population can be expanded through passaging, characterization 
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of this population will be required by the FDA to confirm the degree of purity and 
identity of the cell population and to evaluate the variability related to 
differentiation potential, growth rates, etc. that may exist between cells obtained 
from different donors or the same donor at different time points.  
 
We found that the newly established passage density of 5,000 cells/cm2 
consistently expanded the isolated cell populations ex vivo to 80% confluence, 
and prevented over confluence that can potentially alter the cells’ phenotype. 
Recent work suggests that lower passage densities may reduce population 
doubling times of MSCs 119. Thus, future work investigating the optimal 
parameters for maximizing cell yields in the shortest amount of time will be 
beneficial to improving our process efficacy and reducing overall costs. 
 
The fabrication of individual constructs utilizing our novel pin-plate design has 
significantly streamlined the manufacturing process.  The rate of success for 
capturing and constraining the delaminating monolayer to an appropriate length 
significantly improved from about 30% with the old protocol to 100% with the 
novel pin-plate approach. In a few constructs, the contraction of the tissues 
around the pins post-delamination, led to very thin constructs that tore off the 
pins. Future studies will need to investigate factors that influence tissue roll-up 
including growth factors, pin locations, and time in culture, to improve the 
longevity of our 3D construct fabrication process.  
 
The use of the pin-plates decreased labor and eliminated the variability 
associated with using a technician. This allowed for more accurate evaluation of 
variability between and within constructs engineered from different cell 
populations. Additionally, because a technician is not required to transfer 
monolayers to a new plate and manually constrain them with pins, a single 
technician can fabricate many more constructs in the same amount of time. The 
increased ability of the grafts to survive in vitro will be critical for increasing the 
sample sizes per batch required to adequately characterize the resultant tissue. 
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The rate-limiting step of the construct manufacturing process now shifts to our 
ability to efficiently exchange and add media to each plate. Therefore, future 
experiments were designed to include an automated bioreactor system, capable 
of feeding multiple plates at once. 
 
The relative variability in the average tangent modulus of engineered constructs 
was relatively high (~50%). This was in part due to the significantly higher 
modulus of construct fabricated from donor 1 cells compared to those made from 
cells of the other donors. Exclusion of donor 1 constructs from analysis of BLB 
mechanics shows that variability among donors is greatly reduced with an 
average tangent modulus of 1.7±0.2 MPa and a relative variability of across all 
donors of 12%. While general morphology was similar across all groups, donor 1 
qualitatively exhibited more aligned collagen as seen in polarized images of 
picrosirius red staining. This increase in collagen alignment may have led to 
increased mechanics of these tissues.  
 
While ECM variability may explain the mechanical differences of our constructs, 
the source of this variation is unknown and likely related to variations in the initial 
cell populations obtained from each donor. To control for this variation, further 
identification and characterization of the cell population immediately prior to 
plating is needed to establish a purified starting population required for construct 
fabrication. While it may be impossible to completely eliminate heterogeneity 
within the starting cell population, the identification of specific cell properties or 
ranges of cell properties indicative of successful end-product performance, will 
be useful for improving process efficiency and construct quality. Defining 
acceptable cell criteria will also be important for CGMP compliant process 
validation that will require the identification and control of variation with the 
manufacturing procedures.  
 
Despite differences observed in final construct properties among donor cell 
populations, significant differences in cell yields during passaging were not 
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observed. Alternative methods for characterizing cells during the construct 
fabrication process, such as relative gene expression analysis, may be needed to 
identify additional sources of variability that may exist between donor 
populations. Additional information about the donor (health history and age of the 
animal), may also be useful in identifying sources of variations that can influence 
the process results.  In addition to adequate cell characterization, the 
identification of suitable construct properties and specifications, indicative of the 
efficacy of tissue regeneration in vivo is a significant challenge in the field of 
tissue engineering. Systematic data collection of much larger sample sizes within 
a tightly controlled, well-characterized manufacturing system is needed to help 
identify new in vitro targets that are more representative of the construct’s 
therapeutic effect in vivo.  
 
In conclusion, the novel methods described in this chapter have led to a 
standardized process for fabricating uniform and reproducible constructs. Future 
studies designed to optimize our process will concentrate on investigating plating 
densities, expression of ligamentous markers, and construct mechanics. 
Additionally, our newly introduced methods demonstrate the standardization of 
only the ligament part of the BLB manufacturing process. Cells grown under 
osteogenic culture conditions may have vastly different growth rates and 
properties.  Thus, we will need to develop custom protocols to standardize 
passage densities, culture time, and growth conditions to optimize their 
osteogenic potential in vitro.  
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Chapter 4  
Characterization of a MSC Population Required for 
Scaffold-less Construct Fabrication 
4.1 Introduction 
Despite the standardization of our MSC isolation and expansion methodologies, 
the mechanical properties of constructs fabricated from the bone marrow 
obtained from different donors varied. This variation was likely attributable to 
subtle differences in the starting cell populations of the extracted MSCs. Thus, it 
is necessary to further define and control the starting cell population in order to 
validate our manufacturing process, ensure a more consistent and well-defined 
end product, and comply with current CGMP regulations. Additionally, to improve 
the translational applications of our BLB technology, the ability to produce human 
derived constructs using our current fabrication method should be evaluated. 
 
Within our current ligament manufacturing protocol, MSCs cultured in fibrogenic 
media attach to, proliferate, and differentiate towards a tendon/ligament-like 
lineage over successive passages before being seeded to form a self-
delaminating monolayer. However, extensive characterization of these cells 
immediately prior to final seeding has not been performed and requires sufficient 
analysis to evaluate and define the composition, function, and ligamentous 
differentiation of this starting MSC population. 
 
Human MSCs (hMSCs) have been shown to differentiate into a variety of tissues 
including tendon, bone, muscle, and fat. However, cell surface similarities 
between MSCs and tendon fibroblasts and the lack of a specific tendon marker 
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make characterizing the differentiated tendon phenotype difficult. The use of 
gene expression data can be used to describe differences in the regulation of 
tendon-related ECM production even though they are not directly indicative of 
protein quantity. Work by several authors has utilized a combination of gene 
targets, including Col-1, Col-3, TenC, and scleraxis, to identify induction of MSCs 
toward a tendon-like lineage 27,183,185. Scleraxis, although expressed in other cell 
types such as osteocytes and chondrocytes, is considered highly specific for 
ligament differentiation and believed to also regulate tenomodulin and Col-1 
expression. The expression of Runx 2 and alkaline phosphatase (ALPL) is 
commonly associated with differentiation to an osteogenic lineage and can be 
used as a negative control to confirm the commitment towards ligament versus 
bone. 
 
The characterization of human MSCs is not trivial. MSCs isolated from bone 
marrow aspirations have been shown to be few in number with roughly 1:10,000 
nucleated cells attaching to the culture dish 30. Additionally, contamination of the 
MSCs with plastic adherent hematopoietic debris complicates the isolation of a 
purified MSC population. As such, successive expansion of the extracted MSCs 
is required to amplify and purify cells for subsequent characterization assays. In 
addition to their plastic adherence properties, MSCs are characterized by leptin 
receptors (CD45, 95, 105) and their ability to differentiate towards multiple 
lineages. Due to the increasing use of bone marrow derived MSCs in tissue 
engineering applications and regenerative cell therapies, several companies and 
researchers have begun investigating strategies for large-scale MSC production 
using CGMP compliant conditions. The use of sophisticated methods of 
manufacturing and characterization that are in accordance with international 
standards for MSC identification (i.e. plastic-adherence, cell surface markers, 
and differentiation potential) and allow for a well-defined cell population to be 
produced, are well beyond the capabilities of our laboratory.   
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Fortunately for us, well-defined MSCs are commercially available from 
companies such as Lonza and Rooster Bio.  The utilization of these MSCs 
eliminates a significant part of the manufacturing process that involves the 
expansion and characterization of a consistent MSC starting population. It 
eliminates the extensive testing required to identify and describe the composition 
and phenotype of MSCs isolated with our current techniques. Additionally, the 
time saved by utilizing a ready-made, purified cell source would shorten 
fabrication time and improve the overall process efficiency. However, we have 
not tested the ability of an undifferentiated MSC population to differentiate to 
tendon-like lineage and directly form a 3D construct via our existing 
manufacturing protocol. 
 
The objective of this study was therefore to utilize a commercially available and 
well-characterized hMSC population as our starting material and evaluate the 
ability of the hMSC to differentiate to tendon and form a 3D construct using our 
current BLB fabrication process. If successful, this will expedite the translational 
application capabilities by identifying a clinically relevant, regulatory compliant, 
pre-manufactured starting material for ligament/tendon construct fabrication. The 
characterization of the ligamentous MSC lineage throughout the ligament 
fabrication process via gene expression will be used to establish process 
validation criteria of the in-process intermediates, and will more accurately define 
the specifications and properties of our graft. 
 
4.2 Methods 
4.2.1 Formation of Ligament and Bone Constructs from hMSCs 
First, human MSCs (Lonza and Rooster Bio) were removed from liquid nitrogen 
storage and placed in a 37°C water bath. Immediately following the thawing 
process, the entire volume of cells and media was transferred to a sterile 15 ml 
conical containing at least 3 times the volume of warmed GM. Next, the cell 
suspension was centrifuged at 1500 rpm for 5 min at 37°C. The supernatant was 
 75 
aspirated and remaining cells were re-suspended in fresh GM and counted. 
Viable cells were seeded onto sterile polystyrene tissue culture plates at a 
density of 21,000 cells/cm2. Plates were immediately induced towards bone and 
ligament linages through the addition of osteogenic and fibrogenic media, 
respectively. Both hMSCs manufacturers provided extensive characterization of 
the starting cell populations. De-identified characteristics of the donor and lot 
information of cells are described below in Table 2.  
 
Table 2 Donor and Lot Details of Cells Used for Construct Formation 
Manufacturer Patient Sex Patient Age Lot # Passage Frozen 
Lonza Male 23 056 P2 
Rooster Bio Male 30 007 7.2 Pop. Doubling 
Rooster Bio Female 33 012 7.6 Pop. Doubling 
 
At various defined stages of our fabrication process, cells and tissue were 
harvested for subsequent qPCR analysis at 0, 4, 8, and 12 days. These time 
points correspond to the initial plating, growth phase, differentiation phase, and 
3-D roll-up phase of the self-delamination tissue fabrication process, respectively. 
An additional 3 constructs were fabricated and allowed to remain in a 3D 
configuration in vitro until day 15 for subsequent mechanical and histological 
analyses of the formed 3D tissue. A diagram of the experimental set-up and 
sample size for each lot of donor cells is shown in Figure 4.1. 
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Figure 4.1 Experimental Design for hMSC Construct Analysis. Temporal gene expression 
was analyzed at day 0, 4, 8, and 12 time points that corresponded to various aspects of the 
construct manufacturing process. Mechanical and histological analyses were performed 
exclusively on day 15 (3 days following roll-up) constructs. 
 
4.2.2 Cell and Tissue Preservation for RNA Extraction 
Isolation of ribonucleic acid (RNA) was performed on cell and tissue isolates, at 
0, 4, 8, and 12 days. Day 0 cell suspensions, directly from the manufacturer, 
were immediately placed in a 2 ml cryovial and centrifuged at 1500 rpm for 5 min 
at 25°C. Following centrifugation, the supernatant was removed and the cryovial 
was submerged in liquid nitrogen for a minimum of 30 seconds to freeze the 
resultant cell pellet. Cells and tissue recovered at 4, 8, and 12 day time points 
were first trypsinized from the culture surface, before being placed into 2 ml 
cryovials and centrifuged at 1500 rpm for 5 min at 25°C. Following removal of the 
supernatant, the resultant cell/tissue concentration was frozen in liquid nitrogen 
for at least 30 sec. All cryovials were stored at -80°C following freezing until 
required for further processing. 
 
4.2.3 Histological Analysis of Tissue Constructs 
Histological analysis of the constructs was performed to investigate the general 
morphology and distribution of collagen and mineral within the constructs. 
Methods for histological and immunohistochemical staining have been described 
previously in section 3.4.7. Briefly, at 3 days post 3D construct formation (day 
15), constructs were rinsed with phosphate buffered saline (PBS, Sigma-Aldrich) 
and flash frozen in tissue freezing medium. Sample sections (10 µm, Milipore 
Cryostat) were prepared for histological and immunohistochemical analyses. 
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Tissue structure and collagen distribution were determined using H&E and 
collagen-1/DAPI immunohistochemical staining, respectively. Deposition and 
distribution of calcified mineral was determined with Alizarin Red S staining 130. 
 
4.2.4 Gene Expression Analysis 
Total cellular RNA was isolated by lysis in Trizol (Qiagen) followed by a one-step 
phenol chloroform-isoamyl alcohol extraction. RNA isolation was performed on 
undifferentiated MSCs (n=1 sample, per donor) and cells harvested at days 4, 8, 
and 12 of the BLB fabrication process (n=3 samples, per time point and donor) 
by using a miRNeasy Kit (Qiagen) and treating with DNase I (Qiagen). 
Osteogenic constructs were simultaneously fabricated and evaluated at 
equivalent day 4, 8, and 12 time points (n=1 sample, per time point and donor). 
The amount and integrity of RNA were quantified using a bio-analyzer system 
(Nanodrop 2000). A total of 200 ng of RNA was reverse-transcribed using an RT2 
HT First Stand kit (Qiagen). The amount of cDNA in each sample was analyzed 
using a Nanodrop system, and 200 ng of the cDNA template was used for each 
qPCR reaction. The cDNA was amplified in a CFX96 real time thermal cycler 
(BioRad) using a Taqman gene expression assay kit. The level of expression of 
mRNA transcripts of each target gene was calculated as 2-(dCt) and normalized to 
GAPDH using methods of Schmittgen and Livak 94. A list of TaqMan® Gene 
Expression Assays used in this experiment is shown in 
 78 
Table 3. The qPCR reactions were run in duplicate and results are presented as 
averaged target gene expression (mean ± standard error) normalized to GAPDH 
for all donors. 
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Table 3 TaqMan Gene Expression Assays (Applied Biosystems) used for qPCR 
Gene Symbol Gene Name Assay ID 
GAPDH 
Glyceraldehyde-3-Phosphate 
Dehydrogenase 
HS02758991_g1 
COL1A1 Collagen I – α1 Hs00164004_m1 
COL3A1 Collagen III - α1 Hs00943809_m1 
TNC Tenascin C Hs01115665_m1 
SCXA/B Scleraxis Hs03054634_g1 
RUNX2 Runt-related transcription factor 2 Hs00231692_m1 
ALPL Alkaline phosphatase Hs01029144_m1 
 
4.3 Results 
4.3.1 Formation of Human Bone and Ligament Constructs 
We successfully fabricated three-dimensional bone and ligament constructs 
utilizing undifferentiated MSCs using our current BLB fabrication protocol. The 
hyper-confluent monolayers successfully self-delaminated and were successfully 
captured on the custom 35 mm pin plates, with pin anchors set 20 mm apart 
(Figure 4.2). The constructs remained intact on pins for 3 days post roll-up and 
then were harvested for mechanical and histological testing.  
 
Figure 4.2 hMSC Ligament Construct. Dimensions of 3D tissue are approximately 20 mm x 
0.5 mm x 0.5 mm 
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4.3.2 Mechanical Properties of Ligament hMSC Constructs 
Ligament constructs were mechanically tested utilizing a custom built 
tensiometer as described earlier. Briefly, the constructs were removed from pins 
and tested 3 days following formation of a 3D construct. The stress vs. strain 
data for each sample are shown in Figure 4.3. Strain data were obtained through 
digital image correlation of markers on the tissue and calculated using methods 
described in section 3.4.6. The maximum tangent modulus was calculated for 
each sample by computing the slope of the nominal stress vs. nominal strain 
curve. The mean tangent modulus was 12.0 ± 0.2 kPa. No significant differences 
in the mechanical properties of the tissues were observed between cell lots (n>2 
per donor). Due to the limited number of bone samples, the bone constructs were 
not mechanically analyzed.  
 
 
Figure 4.3 Mechanics of hMSC Ligament Constructs. All tests are shown until failure. 
 
4.3.3 Characterization of the Human-Derived Tissue Constructs 
Morphologically the constructs were similar in appearance to previously 
described constructs derived from ovine cells. The constructs were composed 
primarily of Col-1 with viable nuclei present throughout the tissue (Figure 4.4B). 
The H&E staining showed that the constructs were composed of relatively 
amorphous tissue with more highly aligned collagen regions observed on the 
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periphery of the tissue (Figure 4.4A). Alizarin red staining showed no calcified 
mineral present within ligament constructs (Figure 4.4C). However, alizarin red 
staining of bone constructs did confirm the presence of a small amount of 
calcified mineral (Figure 4.4D). Differences in the gross morphology and 
distribution of Col-1 between engineered bone and ligament constructs were not 
observed. Morphological differences between constructs derived from separate 
donor populations were also negligible. 
 
 
Figure 4.4 Histology of Human-Derived Constructs A) H&E (X4), B) Collagen-1/DAPI 
immunostaining (X4), C) Alizarin staining (X40) of ligament constructs, and D) Alizarin 
staining of bone construct (X40) 
 
4.3.4 RT-PCR Results 
Gene expression relative to GAPDH expression was analyzed via quantitative 
PCR (qPCR) for all tissue samples. Average gene expression was determined by 
combining analysis across all donor cell populations. Expression of genes 
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typically associated with tendon and bone differentiation was analyzed and 
compared over time in culture (days 0, 4, 8, and 12) and is shown in Figure 4.5. 
Relative gene expression of tendon differentiation markers Col-1, Ten-C, and 
Scx were significantly increased at day 8 compared to undifferentiated MSC 
starting cell populations. While the expression of Col-3 was increased by day 8 
(P=0.07), the increased expression was not significant until day 12. The 
expressions of ligament markers Col-1, Ten-C, and Scx peaked at day 8 before 
dropping at day 12 to undifferentiated (day 0) expression levels. Additionally, 
expressions of Runx-2 and ALPL within our ligament constructs were significantly 
less at days 8 and 12 compared to undifferentiated MSC populations. The down-
regulation of these bone-specific markers at day 8 and 12 time points further 
confirms the induction of the MSCs towards a tendon/ligament lineage. 
 
The average relative gene expression of bone constructs was also evaluated 
(qPCR) at days 0, 4, 8, and 12 of culture (Figure 4.6). Expression of Col-1 and 
Col-3 increased with increased time in culture with approximately a two-fold 
increase compared to the undifferentiated MSC expression levels at day 0. The 
increase in Col-1 and Col-3 markers is consistent with an increased production of 
ECM material necessary for 3D tissue formation. As expected, significant 
increases in the expression of ligament-specific markers Ten-C and Scx were not 
observed in MSCs induced to an osteogenic lineage. Conversely, expression of 
bone-specific markers Runx 2 and ALPL did increase over time in the MSCs 
induced to an osteogenic lineage.  
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Figure 4.5 Relative Gene Expression of hMSC Ligament Constructs. (#) denotes 
significance with respect to undifferentiated MSCs. 
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Figure 4.6 Relative Gene Expression of hMSC Bone Constructs. (#) denotes significance 
with respect to undifferentiated MSCs. 
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4.4 Discussion 
The results of this study validate the use of our manufacturing process to 
engineer 3D tendon and bone constructs starting from a well-characterized 
commercially available cell source. Both tendon and bone tissues, fabricated 
directly from an undifferentiated MSC population and expanded to ligamentous or 
osteogenic lineages during the fabrication process, successfully formed 3D BLB 
constructs. The prevention of the labor intensive cell passaging steps in this 
newly developed manufacturing protocol reduces construct fabrication time by 
removing the need to define and characterize specific tendon and bone cell 
populations prior to use within our system and eliminating the need for continual 
monitoring by a highly trained technician. 
 
The ability of MSCs to differentiate towards a ligament phenotype in culture was 
demonstrated through the analysis of gene expression data normalized to 
GAPDH. No significant changes in relative gene expression were observed 
between undifferentiated MSCs and MSCs induced to a ligamentous lineage for 
4 days. However, following 8 days in fibrogenic media, the cells recovered from 
the confluent monolayer had a higher gene expression of ligament-specific 
markers of Col-1, Col-3, TenC, and Scx compared to the undifferentiated cells. 
Expression of bone-specific markers Runx2 and ALPL were also down-regulated 
at the 8-day time point. Within our fabrication process, the day 8 time point is 
believed to be associated with an increased synthesis of ECM as the cells form a 
confluent monolayer with sufficient matrix integrity to allow for self-delamination.  
 
Following peak ligament-specific gene expression at day 8, the average 
expressions of Col-1, TenC, and Scx in cells cultured for 12 days were reduced 
to levels observed in the undifferentiated MSCs. Following the formation of a 3D 
construct at day 12, the protein synthesis of the cells may have switched from 
high rates of ECM synthesis to maintenance of existing ECM. It is important to 
note that gene expression is not always indicative of protein expression. In fact, 
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despite the finding that gene expression at 12 days was equivalent to that of 
undifferentiated MSCs, the overall amounts of tendon proteins within the 
developing tissue may have been increased. Histological staining with Col-
1/DAPI confirmed a high abundance of Col-1 within the tendon portion of the 
constructs despite a decrease in relative gene expression of Col-1 at day 12. 
 
MSCs cultured in osteogenic media demonstrated a decrease in ligament-
specific makers and an increase in bone-specific markers (Runx-2 and ALPL) 
with time. Histologically small amounts of mineral were seen within the bone-
differentiated engineered tissue. However, the relatively small amount of 
mineralization suggests that additional time in vitro may be required to elicit more 
substantial bone-like phenotypical changes in the bone region of the engineered 
tissue. 
 
The earliest time point suitable to correlate the mechanics of our 3D tissues with 
gene expression immediately following delamination (day 12), was at three days 
following roll-up (or day 15 of fabrication process) because mechanical analysis 
of the material properties of our tissue requires accurate construct dimensions. 
Tissue monolayers immediately following delamination are amorphous and 
require sufficient time in culture to contract and uniformly align between the two 
constraint pins. Evaluation of the constructs before a uniform diameter had been 
established would have yielded inaccurate mechanical results. The moduli of our 
constructs at this three-day time point were significantly more compliant than 
previously reported tissue properties described in Chapter 2. This suggests that 
significant changes in ECM structure and composition may occur within tissues 
with increased time in culture. 
 
While the average relative gene expression with time in culture was similar 
between hMSC donors, the degree of relative gene expression varied. Despite 
these differences between groups, observable changes in construct histology or 
mechanics were not observed. However, more detailed assays looking at protein 
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content within our constructs may be needed to further characterize ligamentous 
differentiation and construct properties among donor samples. 
 
Continued evaluation of our fabrication process utilizing a well-defined cell 
population is needed to identify and control sources of variation within the 
manufacturing system. The use of standardized markers of gene expression may 
provide suitable specification necessary to demonstrate production consistency 
and graft effectiveness in vivo.  
 
In summary, use of characterized, undifferentiated, bone marrow derived hMSCs 
is an acceptable starting cell population for the fabrication of scaffold-less 
constructs. As these MSCs are capable of differentiating towards both 
ligamentous and osteogenic lineages during the construct formation process, 
significant time associated with expansion and characterization of a pre-
differentiated tendon or bone-like MSC population can be eliminated. 
Additionally, sufficient quantities of these well-characterized cells can be readily 
obtained from CGMP compliant manufacturers, making them an ideal input 
material for our translational manufacturing process. 
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Chapter 5  
Bioreactor Manufacturing of Multi-Phasic Tissue 
Constructs 
5.1 Introduction 
In addition to establishing a robust protocol capable of producing uniform 
constructs reproducibly, significant hurdles remain with respect to commercial 
manufacturing of an engineered product. Transitioning the laboratory 
concept/methods into a well-characterized medical product/process is a 
significant challenge, commonly underestimated by researchers in tissue 
engineering and regenerative medicine fields. In addition to meeting regulatory 
requirements to ensure consistency and safety of any product, the manufacturing 
system must be scalable and cost-effective to be sufficiently economically viable 
to displace current treatment options. Addressing manufacturing issues related to 
quality control, cost-effectiveness, and large-scale production early in the 
research stage, can overcome problems that typically slow development, limit 
investment, and escalate costs limiting the clinical translation and availability of 
the treatment to patients in need. 
 
5.2 Background/Motivation 
Despite significant advancements in the field of tissue engineering, relatively few 
products have realized commercial success as tissue substitutes 22,102,103. 
Several challenges still remain for translating tissue-engineering technologies 
from bench to bedside. In addition to demonstrating clinical effectiveness, cost-
effective manufacturing processes are needed that comply with the current 
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quality and safety regulations 1,175. Failure to adequately consider the likely cost 
of manufacturing early in the developmental stage has been recognized as a 
limiting factor for commercial success of technologies in the field 5. Traditional 
manual laboratory tissue culture techniques are often not economical at large 
clinical scales and have inherent variability and contamination risks. However, 
due to their widespread use, simplicity, minimal development time, and low initial 
costs, these processes are still used to rapidly advance into clinical trials and the 
marketplace 24,38.  
 
For example, Carticel™, recently acquired by Aastrom Biosciences, Inc. (Ann 
Arbor, MI), is an autologous cell transplantation product used to repair articular 
cartilage injures in the knee. Carticel™ is manufactured via manual techniques 
performed by trained technicians in a serologic clean room. Briefly, cells are 
isolated from the patient and expanded on tissue culture flasks to a sufficient 
number needed for therapeutic use 110. This process requires a large number of 
manual labor-intensive manipulation steps. A manual process, though perhaps 
more feasible and economical on a small-scale during early process 
development, is generally regarded as high risk due to the increased potential for 
contamination 112,132. Additionally, inherent differences in processing techniques 
between individuals, especially with technically challenging methods, can lead to 
process inconsistencies and end product variability 177. Furthermore, as 
production demand increases, scale-up will require multiple manual processes to 
be performed in parallel, requiring additional technicians and generating 
substantial labor costs. As a result, the overall cost of production of such 
products tends to be high and can limit clinical success when the cost-benefit of 
the product is evaluated against competing and often simpler therapeutic 
strategies 133. The risk of commercial failure can be greatly reduced by 
considering the economic viability of the product throughout the developmental 
process 176,178. Automating manual tissue-culture processes through the use of 
bioreactor systems can provide a means to standardize the culture process, 
tightly control culture environment, remove user-dependent operation, and 
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establish a cost-effective tissue manufacturing process to meet large-scale 
clinical demand 24,175. 
 
Automated bioreactors have long been used in tissue-engineering manufacturing 
and typically involve streamlining traditional 2D cell culture processes (cell 
selection, expansion, differentiation, etc.) 65,131,173. While important, these cell 
manufacturing processes are often only the starting point for many tissue 
engineering strategies that utilize well characterized cell populations for tissue 
growth. Thus there is a need to foster automated bioreactor-based systems fit for 
the development of reproducible 3D engineered constructs. A closed, 
standardized, and operator-independent bioreactor system would have the 
potential to ensure safety and regulatory compliance and enable cost-effective, 
large-scale, in vitro tissue production 1,151. 
Recently, Advanced Tissue Sciences developed an automated system for large 
scale manufacturing of their human fibroblast derived dermal substitute, 
Dermagrat™ (currently manufactured by Organogenesis, Inc. (Canton, MA)). 
Dermagrat™ consists of living cryopreserved allogeneic dermal fibroblasts 
seeded onto a bio-absorbable polyglactin mesh scaffold used for treatment of 
chronic skin wounds such as diabetic foot ulcers 109. The entire manufacturing is 
performed in a closed bioreactor bag, eliminating user-dependent variability and 
shielding the culture process from risk of contamination. The bag also serves as 
a transport container. Following injection of cells into the system, the bioreactor is 
only externally manipulated until the graft is thawed and utilized in the operating 
room.  
 
In addition to minimizing contamination risk, a closed bioreactor system can 
precisely control and maintain the tissue culture environment. Tissue growth and 
development is highly responsive to environmental factors (pH, temperature, 
nutrient concentration, etc.), and as such, the entire fabrication process is critical 
to the integrity of the final product and must maintain a high level of control to 
meet the rigorous current good manufacturing practice (CGMP) standards 
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required by the Food and Drug Administration (FDA) to ensure tissue safety and 
manufacturing consistency (Code of Federal Regulations, CFR 21). 
 
The current BLB open manufacturing process is a labor-intensive one consisting 
of a multiple steps in an open-environment, to manually combine several tissue 
phases and form the multi-phasic graft. This labor-intensive process significantly 
limits the technician’s BLB manufacturing capacity and is one of the greatest 
factors impacting cost of production with scale.  
 
Current automated bioreactor systems for 3D tissue fabrication are product 
specific and/or not commercially available. As no bioreactor currently exists for 
the fabrication of our unique BLB construct in a single vessel, a novel bioreactor 
must be developed. As with current automated manufacturing systems, the 
bioreactor design should be user independent, only externally manipulated, 
sterile, and scalable. It must also recreate the unique multi-step formation 
process incorporating bone and ligament tissues engineered from distinctive cell 
populations into a single construct. As such, the current protocol developed in 
Chapter 3, consisting of Ficoll isolated cells, standardized passage density, and a 
novel pin-plate method for capturing spontaneous monolayer delamination, must 
first be modified as it still includes several technician dependent steps limiting the 
automation and scale of the process. 
 
Firstly, the protocol for BLB fabrication described in Chapter 3 requires the 
simultaneous culture of bone and ligament monolayers. A trained technician, in a 
separate tissue culture plate, performs the combination of these distinct tissue 
types following their delamination. To facilitate formation of a single BLB 
construct within a single-closed vessel, the formation of the BLB construct must 
occur sequentially within the same chamber. Secondly, to engineer BLB 
constructs of sufficient size (>4 cm diameter) for use as an ACL graft 
replacement, at least four constructs must be manually transferred by a 
technician into a new plate and aligned in parallel to allow fusion of the grafts 
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with each other to form a single uniform construct. This labor-intensive step of 
the fabrication process must be eliminated to facilitate construct fabrication within 
a closed, hands-off bioreactor system. The utilization of larger tissue culture 
plates with increased surface area may allow for larger monolayers and resultant 
3D construct diameters following delamination. Thirdly, for the sequential 
formation of bone and ligament tissue within a single vessel, the timing of cells 
introduced into both the bone and ligament fabrication process will have to be 
modified. To maintain a consistent starting cell population for tissue formation as 
determined in Chapter 3, bone and ligament cells must be expanded and 
cryogenically preserved at appropriate time points (passage 3 for ligament and 
passage 4 for bone). The efficacy of cryogenically recovered cells in forming a 
robust, self-delaminating monolayer and BLB construct has not been evaluated 
by our laboratory. The utilization of a cryogenically preserved allogeneic cell line 
will also allow for a consistent and well-characterized population of cells to be 
used for all experiments and will eliminate donor variability between tissues. 
Following these process changes, the BLB manufacturing protocol will be 
replicated in a closed, automated bioreactor system, resulting in a continuous 
multi-tissue constructs without any internal manipulation by the technician. As no 
such system currently exists, the goal of this study was to design, build, and test 
a novel automated bioreactor to fabricate a single ACL graft in a closed-system 
chamber.  
 
To minimize contamination and technician variability, and to provide economy of 
scale, the bioreactor was designed to be closed, automated, modular, scalable, 
and to require minimal external manipulation. Bioreactor success was measured 
by the ability of the user to form a BLB construct without opening the bioreactor 
or manually manipulating the tissue. Bi-phasic structure of the construct was 
confirmed by chromosomal detection of bone cells (male) within expected areas 
of the construct. BLB construct structure and function were evaluated 
histologically (H&E, picrosirius red, alizarin red) and mechanically (tangent 
modulus, extensibility) at 1-week, post-3D construct formation. The histological 
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and mechanical properties of the current BLB fabrication process were used as 
the standards for comparison, since the current protocol described in Chapter 3 
generates ACL grafts that effectively regenerate ligament in vivo (data not 
shown).  
 
5.3 Significance 
This study addresses the significant manufacturing and bioprocessing challenges 
inherent to the commercialization and translation of tissue engineered products 
from laboratory to clinic. In addition to demonstrating clinical efficacy and meeting 
regulatory standards, new tissue engineered products need to be cost-effective 
manufacturing processes to deliver the cost-benefit ratio needed to compete with 
alternative therapeutic options. Automated, closed bioreactor systems can 
provide the means for the development of standardized, cost-effective, and safe 
manufacturing of engineered tissues for clinical applications. Current bioreactor 
systems for 3D tissue fabrication are highly product-specific and often not 
commercially available. Therefore, a novel bioreactor design is required for 
sterile BLB graft fabrication and can fill an important knowledge gap in the field. 
The development of an automated manufacturing system during an early 
research stage has the potential to significantly lessen the technical, regulatory, 
and commercial barriers that tissue-engineering technologies are likely to 
encounter in the future pre-market stages. This development may also serve as a 
model or platform for other tissue systems or tissue-engineering technologies to 
streamline their associated laboratory processes into safe, reproducible, suitably 
scaled tissues for clinical studies.  
 
5.4 Experimental Design 
The development and design of a novel bioreactor culture system for closed, 
automated BLB manufacturing can be divided into two steps. The first step is to 
eliminate the manual steps associated with the current BLB fabrication 
processes. In particular, the user-dependent combination of separate bone and 
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ligament tissues into a single vessel and the fusion of multiple BLB constructs to 
achieve one construct with a diameter of suitable size for ACL reconstruction, 
must be eliminated. The second step is to design and validate a closed, 
automated, bioreactor system to recreate the adjusted manufacturing protocol.  
 
Process methodologies were performed utilizing ovine-derived cell populations 
due to the large amount of knowledge associated with their ability to form a multi-
phasic BLB construct. To eliminate timing issues associated with the sequential 
formation of multiple tissues, cryopreserved cell populations were used to form 
multi-phasic BLB constructs. Male and female cell populations were used to 
make bone and ligament tissues, respectively, to confirm the co-culturing of 
multiple tissue types following construct formation.  
 
5.5 Step 1: Elimination of Manual BLB Manufacturing Processes 
Previously described methods for BLB fabrication require the simultaneous 
culture of bone and ligament monolayers in separate culture dishes. Forming the 
actual multi-phasic BLB graft requires the timed, manual transfer of two 3D bone 
constructs onto a confluent ligament monolayer prior to the monolayer’s 
delamination. The delicate timing and difficulty associated with manually 
performing this process make it difficult to replicate in a closed bioreactor design. 
The sequential preparation of bone and ligament tissues in a single culture 
vessel would greatly eliminate the technical complexities of this process and 
simplify the bioreactor design. However, the ability to form a confluent, 
spontaneously delaminating ligament monolayer from a single fibrogenic cell 
suspension while in the presence of pre-formed bone constructs had not been 
evaluated by anyone to the best of our knowledge. 
 
The current process of BLB construct fabrication requires the manual 
combination and fusion of multiple 3D BLB constructs to form a construct of 
suitable diameter for use as a graft in ACL reconstruction. Again, from a design 
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perspective, it would be advantageous to eliminate this manual combination step 
and fabricate a single construct of sufficient size for implantation within a single 
vessel. The inclusion of these protocol changes to the current BLB fabrication 
process will simplify the design of a closed, “hands-off” bioreactor system. 
 
5.6 Methods 
5.6.1 Isolation of MSCs 
Bone marrow was aspirated from the iliac crest of sheep using a Monoject Illinois 
needle (Sherwood Medical Company, St. Louis, Mo) with the animal under 
general anesthesia induced by intravenous propofol and sustained with 
inhalation of isoflurane in oxygen. A minimum of 15 ml of bone marrow volume 
was collected using heparinized needles and dispensed into EDTA blood 
collection tubes (BD, San Jose, Ca.) for processing. 
 
The marrow was filtered through a 100 mm filter to remove solid debris and 
consolidated into a single 50 ml conical. An equivalent volume of Dulbecco’s 
Phosphate-Buffered Saline (DPBS) pH 7.2 (Gibco BRL Cat# 14190-144) was 
added. The marrow solution was slowly added to a 15 ml layer of Ficoll-Paque 
Premium (GE Healthcare, Munich, Germany) contained within a separate conical 
and centrifuged (AccuSpin FR; Beckman Coulter Inc., Fullerton, CA) at 600 g for 
30 minutes at 25°C. 
 
The upper layer containing plasma and platelets was discarded, and 
mononuclear cell layers containing the MSC population were transferred into a 
new sterile conical. The cells were suspended in at least three times their volume 
of DPBS and centrifuged at 500 g for 10 minutes. The supernatant was removed, 
and an equivalent volume of ACK lysis buffer was added to the pellet volume, 
lysing any remaining red blood cells. The conical was filled with DPBS and 
centrifuged at 400 g for 5 min. The supernatant was again removed, and the 
MSC pellet was re-suspended in 20 ml of growth medium (GM; DMEM 
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supplemented with 20% FBS and 2% ABAM). Cells were counted utilizing a 
Countess automated counting system and immediately plated at a density of 
40,000 cells/cm2 in a 150 mm tissue culture dish.  
 
5.6.2 Expansion and Cryopreservation of MSCs 
The adherent cell population was allowed to attach for 3 days before the plate 
was rinsed with DPBS to remove any remaining debris or contaminating non-
adherent cell populations. Following plating, cells were immediately cultured 
towards either an osteogenic or ligamentous lineages. Osteogenic growth 
medium consisted of GM supplemented with 600 ng/ml basic fibroblast growth 
factor (bFGF; Peprotech), and 400 ng/ml dexamethasone (dex; Sigma-Aldrich). 
Ligamentous growth medium consisted of GM supplemented with only bFGF. 
Plates were fed either bone or ligament medium every other day. At 
approximately 50% confluence, the plate-adherent MSC populations were 
trypsinized (trypsin-0.25% EDTA), combined into a single conical, and passaged 
at a density of 5,000 cells/cm2 every other day. Following passage three, 
ligamentous derived MSCs (ligament cells) were trypsinized and cryogenically 
preserved. MSCs induced to an osteogenic lineage (bone cells) were passaged 
and cryopreserved after passage four. Cells were cryogenically preserved at a 
concentration of 5x106 cells/ml in GM+10% DMSO (Sigma-Aldrige). One ml 
volumes were aliquoted into 2 ml cryovials (Nalgene) and slowly frozen 
(approximately 1°C/hr) overnight to -80°C. The vial was then transferred into a 
liquid nitrogen freezer for long-term storage. 
 
5.6.3 Thawing and Plating of Cells	  
As needed, cells were removed from liquid nitrogen storage and placed in a 37°C 
water bath. Immediately after the medium turned to liquid, the entire volume of 
cells and medium was transferred to a sterile 15 ml conical containing at least 3 
times their volume of warmed GM. The cell suspension was centrifuged at 1500 
rpm for 5 min at 37°C. The supernatant was aspirated and remaining cells were 
re-suspended in fresh GM and counted. Cell viability was assessed with trypan 
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blue dye (Life Technologies). Recovered cells utilized for tissue formation 
contained greater than 90% viable cells. Cells were seeded onto sterile 
polystyrene tissue culture plates at a viable cell density of 21,000 cells/cm2. Bone 
plates were fed GM supplemented with 400 ng/ml dex, 13 mg/ml ascorbic acid, 5 
mg/ml L-proline, and 600 ng/ml bFGF.  The ligament medium was similar to the 
GM, lacking only the dex. 
 
5.6.4 Preparation of Bone Constructs 
Bone cells were first seeded onto 8-well rectangular tissue culture treated 
polystyrene plates (NUNC Plastics) modified with two metal posts aligned 
longitudinally and centered within the plate 15 mm apart (Figure 5.1A). Medium 
was changed every 2-3 days. Cells became confluent after approximately 12 
days. After 5 days in culture, the dishes had become hyper-confluent, forming a 
monolayer sheet consisting of cells and cell-generated ECM. At this time, the 
medium was switched to differentiation medium (DM; supplemented with 7% HS 
and 2% ABAM) supplemented with 10µl/ml dex, 10µl/ml ascorbic acid/proline, 
and 20µl/ml TGF-B. After approximately 1-2 days in culture, spontaneous de-
lamination of the monolayer occurred. The capturing of the shrinking monolayer 
between the two constraining posts formed 3D cylindrical bone constructs.  
 
Figure 5.1 Custom Pin Plates A) 8-well Bone Plate, and B) 4-well Ligament Plate. The 
locations of the posts were precisely aligned between the bone and ligament plates, 
facilitating the efficient transfer of uniform bone constructs onto ligament plates. 
 
5.6.5 Preparation of Ligament Culture Plates 
Bone constructs were transferred at fixed length onto identical post locations in a 
sterile 4 well-rectangular tissue culture treated polystyrene plate (NUNC Plastics) 
B A 
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(Figure 5.1B). The arrangement of the wells identically matched to 8-well bone 
plates to ensure each ligament well had two bone constructs separated by a 30 
mm distance centered along the long axis of the well. Ligament cells were 
seeded into each well at a density of 21,000 cells/cm2. Cells became confluent 
within 1-2 days and formed a hyper-confluent robust monolayer after 8 days in 
culture. Cells were fed ligament GM every 2-3 days. After 8 days, the medium 
was switched to ligament DM that induced the spontaneous delamination of the 
monolayer within 3-5 days. 
 
5.7 Results 
5.7.1 Sequential Formation of BLB Constructs Within Single Vessels 
Monolayers derived from both bone and ligament cryopreserved MSC lineages 
successfully formed and spontaneously delaminated, demonstrating the ability of 
cryogenically preserved cells to form BLB grafts. Additionally, seeding of 
ligament cells following transfer of bone constructs to the ligament culture 
surface did not interfere with ligament monolayer formation and resulted in the 
successful co-culture of ligament and bone required for BLB formation. The 
delaminating ligament monolayers fully surrounded the bone constructs, 
capturing them within the newly formed BLB construct (Figure 5.2). The diameter 
of the ligament region was noticeably thin (0.3+0.1 mm, n=5) with approximately 
half of the constructs failing in the ligament mid-substance after 2 weeks. The 
results demonstrate the ability to form a BLB sequentially in the same dish by 
first adding bone constructs and then seeding ligament cells. 
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Figure 5.2 BLB Delamination. Bone regions were captured and surrounded by 
delaminating ligament monolayer. The culture surface for each of the 4 wells is 21.8 cm2. 
 
5.7.2 Formation of Large Diameter Tissue Constructs 
Larger pin plates were fabricated utilizing 150 mm tissue culture plates, with a 
culture surface area of 182 cm2, and two metal posts located 50mm apart 
centered and aligned uni-axially. As a control, 100 mm pin-plates, with a culture 
surface area of 82 cm2, were also fabricated as described in Chapter 3. Plates 
were UV treated for at least 1 hour, sprayed with 70% ETOH, and rinsed with 
approximately 20 ml DPBS prior to use. Ligament cells were seeded onto 100 
mm and 150 mm pin-plates and grown into a confluent monolayer, and 
spontaneously delaminated into a 3D construct. Construct diameters were 
compared at a one-week time point following delamination, as shown in Figure 
5.3. The 100 mm pin-plate formed a construct approximately 2 mm in diameter 
(n=3) while constructs fabricated in the 150 mm pin-plates formed constructs 
about 5 mm in diameter (n=3). Pin locations were identical in each of the plates. 
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Figure 5.3 Pin Plate Construct 1 Week Post Delamination. Top: Construct fabricated on 
100 mm plate. Bottom: Construct fabricated on 150 mm plate 
 
5.8 Discussion 
Adding ligament derived MSCs to individual wells, containing strategically placed 
pre-formed 3D bone constructs, formed a BLB construct. This is in sharp contrast 
to previous methodologies that require the combination of 3D bone constructs 
onto confluent ligament monolayers to form the multi-phasic tissue. The results 
demonstrate the feasibility of forming BLB constructs within a single well by 
sequentially seeding cryogenically preserved bone and ligament cells. This 
process adaptation eliminates the need for technicians to combine bone and 
ligament tissues to form a BLB. As cells instead of 3D tissues are input into the 
system, the process can easily be performed sterilely. The elimination of 
technician dependent steps allows for the process to be automated and 
performed in a closed system, which is essential for use within a bioreactor. 
 
The use of cryogenically preserved allogeneic cells also allows for large-scale 
expansion of cells that can be well characterized and used as needed for graft 
fabrication. This is a significant advantage for process scalability compared to 
fresh cells, as the starting cell population can be screened and evaluated before 
investing time and resources into large volume construct production. The 
regulatory perspective requires a well-defined starting cell population. Utilization 
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of allogeneic cells has the advantage of performing this characterization only 
once. Autogenic cells must be characterized for each donor significantly 
increasing the economy of scale and limiting the commercialization potential. 
 
The fabrication of larger diameter grafts formed on the 150 mm plates compared 
to 100 mm plates reveals the ability to control graft size through the manipulation 
of culture surface area. This process eliminates the need for manual fusion of 
multiple constructs by a technician, again, a technician-dependent step that can 
impede the development of efficient, automated manufacturing processes, 
suitable for bioreactor incorporation. Further evaluation of the change of 
construct diameter, passive construct tension, and tissue mechanics must be 
evaluated further. The described methods demonstrate essential protocol 
adaptations that were needed to facilitate fabrication of BLB constructs within 
single well, closed, bioreactor systems. The following sections will describe the 
development of that system. 
 
5.9 Step 2: Bioreactor Development 
5.9.1 Bioreactor Design 
Following the removal of user-dependent steps from the fabrication process, the 
end multi-phasic tissue graft must be replicated within a closed bioreactor 
system. As no current bioreactor system exists, a novel device must be 
designed, fabricated, and tested to confirm that a viable multi-phasic BLB graft 
can be fabricated by user-independent methods within a closed system. The 
bioreactor device shown in Figure 5.4 below was designed based on the 
following design elements and performance requirements. 
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Figure 5.4 Flip Plate Bioreactor System. Approximate dimensions are 7 in x 6 in x 2 inches. 
 
5.9.2 Bioreactor Design Criteria 
• Minimizes Contamination Risk 
o Closed system – completely “hands-off” internal manipulation, 
beginning with the  injection of starting material and ending with 
final construct formation 
o Potential for inline monitoring and media sampling 
o Container suitable for construct preservation, packaging, and 
shipping 
o Consists of FDA compliant materials that are capable of being 
easily sterilized (autoclavable, ethylene oxide) 
! Or the use of disposable elements that can be replaced if 
they come into contact with cell, media, or wastes 
• Eliminates Manual, User-Dependent Processes 
o Automated – capable of being controlled without no reliance on a 
technician 
o Only external manipulation 
! Eliminates user variability and construct consistency 
o Simple to use, easy to operate, and the construct is exposed only 
when needed for patient use 
• Scales Economically 
o Automated – reduce manufacturing time and increase capacity 
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o Modular – capable of incorporating multiple cartridges into larger 
centrally controlled unit 
o Small - Relatively small overall volume to minimize required space. 
 
5.9.3 Performance Requirements of Bioreactor 
• Replicate Current Self-delaminating BLB Fabrication Process  
o Cells, media, nutrients can be added and waste removed on a 
regular basis 
o As suture will be primary method of introducing during ACL repair 
surgery, suture must be made available and easily integrated into 
construct. 
• Form a Continuous Multi-phasic BLB Construct within a Single Device 
 
5.9.4 Cell-Culture for Use in Bioreactor 
Bone and ligament MSC populations were isolated, expanded, and cryogenically 
preserved as described in section 5.6. For use within the bioreactor, bone cells 
were fabricated from male ovine bone marrow while ligament cells were derived 
from female ovine bone marrow. The use of gender-specific cell populations 
allowed for identification of male cell migration between bone and ligament 
regions and verification of co-culturing of two distinct cell populations within a 
single BLB graft. 
 
5.9.5 Flip-Plate Bioreactor Design Summary 
The final bioreactor design, termed a “Flip-Plate”, consists of an enclosed 
chamber, multiple monolayer growth modules, a suture capture system for 
constraining the monolayers during delamination and maturation, and a 
mechanism for enabling tissue co-culturing through magnetic translation of 
tissue. The Flip-Plate bioreactor can be used for the fabrication and co-culture of 
multiple tissue types. As an example, the use of this device for the creation of a 
BLB construct will be described.  
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BLB constructs are made from MSCs differentiated to osteogenic and fibrogenic 
lineages and integrated within the bioreactor to form a continuous multi-tissue 
construct with sufficient structural integrity and mechanical compliance to 
withstand physiological loading when used as a graft for ACL repair without the 
inclusion of exogenous scaffolding. As the culture surface of the bioreactor could 
not be visualized under a microscope, ligament only and bone only constructs 
were fabricated on 100 mm and 60 mm pin plates, respectively, and used as 
process controls. BLB constructs formed within the bioreactor were evaluated 
histologically and mechanically and compared to manually fabricated bone and 
ligament tissues. The details of one or more aspects of the Flip-Plate device are 
described in the accompanying drawings and descriptions below. Other features, 
objectives, and advantages of the invention will be apparent from the detailed 
description and drawings. 
 
5.9.6 Detailed Flip-Plate Design and Description of Use 
Referring to Figure 5.5, cell differentiation, monolayer growth, capturing, and co-
culturing required to make the BLB are accomplished in bioreactor 40.  Though 
this bioreactor is designed for the fabrication of scaffold-free BLB tissue 
constructs, other cell types (i.e. muscle, nerve, etc.) consisting of spontaneously 
or substrate controlled tissue monolayer delamination can be used. Current cell 
culture bioreactors are for the most part designed for non-adherent cell 
suspensions or expansions of cells 131,146,173. These devices do not provide the 
means of capturing and co-culturing delaminated monolayers of multiple tissue 
types that are required for the formation of the multi-phasic BLBs. 
Bone monolayer growth is carried out in module 1, located and sealed into part 
25 of bioreactor 40. Module 1 may be segmented into individual wells 88 to 
form multiple monolayers of various shapes and sizes by the addition of silicone 
barriers 99 to the culture substrate 11. Other barrier materials such as Teflon 
that do not allow for significant cell adhesion may also be used. Bioreactor 40 
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includes manual or automatic translation elements designed to facilitate bone 
monolayer capture (suture 22) and transfer into co-culture (component 3). 
Manipulation of suture 22 arrangements though culture substrate 11 and 
tension (controlled via component 3) can be used to control construct length and 
graft tension within delaminated constructs. During bone monolayer formation, 
MSCs are seeded onto culture substrate 11 of module 1, which preferably 
consists of a sterile polystyrene culture surface coated with or without cell 
adhesion proteins such as laminin.  
Media exchange of module 1 is controlled manually with sterile injection of 
media in an open-environment or automatically with perfused media.  The 
connecting plate 26 contains fittings 5 designed to add and remove media 
contained in each segmented well of module 1. MSCs of the bone monolayer 
growth process contained in module 1 are seeded at an initial density of 
approximately 21,000 cells/cm2. Seeding density may not be critical to the 
success of this invention, affecting only rate of monolayer formation. 
 
Cells proliferate after seeding, forming a monolayer, and differentiate towards an 
osteogenic lineage. While additional serum-containing cell culture media and 
growth factors may be used, a preferred growth medium to optimize cell 
proliferation and promote robust osteogenic ECM production consists of DMEM 
supplemented with 20% fetal bovine serum and antibiotics, along with the 
addition of dex, FGF-b, and ascorbic acid/ L-proline. Growth conditions that must 
be maintained in module 1 include a pH of about 7.4, a medium temperature of 
37°C, and a sterile air environment consisting of up to 20% O2. The medium 
must be exchanged at sufficient rate and volume to prevent depletion of critical 
media constituents by the growing cells; preferably 50% replaced every two 
days. 
 
In reference to Figure 5.6, following sufficient ECM matrix production by the 
seeded cells, a confluent bone monolayer 9 is formed on the culture substrate 
11 after approximately 5 days at the described seeding density (Figure 5.6A). 
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Growth-promoting medium is replaced with differentiation medium consisting of 
DMEM, supplemented with 7% horse serum, antibiotic, transforming growth 
factor-beta (TGF-b), ascorbic acid / L-proline, and dex to induce cell 
differentiation, integration, and passive tension that leads to subsequent 
spontaneous delamination of confluent tissue monolayer. Bone monolayer 9 
delamination within module 1 is captured on sutures 22, forming a 3D bone 
construct 10 as shown in Figure 5.6B. Sutures 22 transverse modules 1 and 2 
and are held in tension by anchoring spools 7 (shown in Figure 5.7). The bone 
constructs 10 are allowed to mature on suture 22; the tissue continues to 
contract and reorganize the ECM structure while constrained under tension. This 
maturation phase occurs over approximately 2 days. However longer or shorter 
times are possible. To facilitate translation and co-culture of the bone 
constructs 10, the bioreactor 40 is inverted (Figure 5.6C). Following the 
release of tension in the sutures 22 by loosening the anchoring spools 7, both 
bone constructs are translated to ligament culture substrate 20 in module 2 
and secured within part 32 (Figure 5.6D). Manual or automated translation of the 
suture via magnets 8 contained within component 3 facilitates this transfer 
(Figure 5.7).  In reference to Figure 5.7, tension is re-established in sutures 22 
(not shown) by pulling the magnets 8 after the anchoring spool 7 has been re-
tightened.  
 
The sutures 22 required for translation reside within tubes (not shown) used to 
minimize sharp edges and friction during translation. These tubes reside in 
grooves 16 of parts 25 and 32. The grooves align the sutures to ensure uniaxial 
insertion across modules 1 and 2 and locate insertion into component 3 to 
interface with the anchoring spools 7 and magnets 8. Sliding grooves for 
magnets 8 are located in part 37. Plates 34 and 35 secure the tubing into the 
grooves 16 and anchor parts 25 and 32 to component 3, attached to 
connecting plate 26. 
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Following translation of bone constructs, MSCs are seeded onto the ligament 
culture substrate 20 of module 2 at an initial density of approximately 21,000 
cells/cm2. The osteogenic medium is replaced with ligament growth medium to 
promote fibroblastic differentiation and production of ligamentous ECM. This 
process requires approximately 8 days in culture. The ligamentous medium 
consists of DMEM supplemented with 20% fetal bovine serum and antibiotics, 
along with the addition of FGF-b, and ascorbic acid/ L-proline. Ligament medium 
is exchanged via fittings 5 attached to the connecting plate 26, at 50% of 
volume every 2 days. Environmental conditions required for ligament growth 
within module 2 are identical to module 1.  
 
Following formation of a ligament monolayer 55 upon the ligament culture 
substrate 20 (Figure 5.8A), the medium is switched to differentiation medium to 
further induce matrix production and cell-matrix tension. The ligamentous 
differentiation medium is composed of DMEM, supplemented with 7% horse 
serum, antibiotic, transforming growth factor-beta (TGF-b), and ascorbic acid / L-
proline. As the ligament monolayer 55 spontaneously delaminates, sutures 22 
capture it, surrounding the bone constructs 10 on substrate 20. The end result 
is a multi-phasic BLB construct 50 that continues to mature (remodel, 
condense, and develop ECM) over time in culture (Figure 5.8B). This maturation 
phase requires approximately 1 week, although shorter and longer periods are 
possible. 
  
The resulting BLB construct can be grafted into the patient at this point or if 
desired, further conditioned mechanically through the physical manipulation of 
sutures 22. If implanted, the incorporated sutures may be utilized to secure the 
graft into the patient during the surgical procedure. It is preferable that a fresh 
BLB construct be used within 3 weeks following formation, as cells and 
appropriate graft tension are difficult to maintain in culture for extended periods of 
times. Alternatively, freezing, acellularizing, or other means of preservation may 
be used to preserve the construct. As will be understood by those skilled in the 
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art, a skilled practitioner may make many changes in the apparatus described 
above without departing from the spirit or scope of the device.  
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Figure 5.5 Exploded view of the Flip-Plate bioreactor design 
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Figure 5.6 Translation of bone constructs within Flip Plate bioreactor. Diagrams A, B, C, 
and D are cross-sectional views that show the capturing and co-culture process. 
D 
C 
B 
A 
10 
9 11 
99 
22 
10 
10 
20 
20 
11 
 111 
 
Figure 5.7 Mechanism for tissue translations of the Flip-Plate device shown in a 
perspective view. Shown as component 3 of Figure 5.5. 
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Figure 5.8 Formation of BLB construct within the Flip-Plate bioreactor. Diagrams A and B 
are cross-sectional views of the BLB captured on suture constraints. 
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5.10 Construct Evaluation Methodologies 
Following successful construct formation, constructs were removed from the 
bioreactor and evaluated as described below: 
 
5.10.1 Mechanical Testing 
Following delamination of the ligament monolayer, the BLB constructs were 
allowed to fuse, forming a uniform cylindrical construct constrained between the 
tensioned sutures. Upon removal of the construct from the bioreactor, separate 
parts of the construct were allocated for mechanics or histological and molecular 
biology analysis. Approximately half of bone/ligament complex was taken for 
histology and molecular biology. The rest was attached to a custom-built tensile 
tester and submerged in DPBS for subsequent tensile testing. The testing set-up 
can be seen in Figure 5.9. Constructs were secured using custom Velcro grips 
and incrementally lengthened to approximate the original length within the 
reactor. Sixty-micron beads were painted onto the surface of the tissue for post 
analysis digital image correlation to extrapolate the tissue-level strain during 
testing. The construct was pulled until failure at a rate of 0.01 /sec. Load and 
strain at failure was recorded. Figure 5.9 is an image of the described testing set-
up of the ligament region of the BLB construct. The missing bone region on the 
right, shown by lack of suture, indicates the region removed for PCR analysis.  
 
 
Figure 5.9 BLB on tensile testing set-up 
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5.10.2 Histological Analysis 
For staining, unfixed samples were placed into TBS medium (Triangle Biological 
Sciences), frozen in cold isopentane, and stored at -80°C until needed. Fixed 
samples were placed in 4% paraformaldehyde (PFA) for 1 hour. The samples 
were then placed into 15% sucrose solution for 1 hr at 4°C and then overnight 
(>12 hrs) in 30% sucrose solution also at 4°C. The constructs were then 
transferred into TBS medium and frozen over dry ice and stored at -80°C until 
needed. Samples were cut to obtain cross and longitudinal sections with a 
cryostat at a thickness of 12 µm, adhered to Superfrost Plus microscopy slides, 
and used for staining. Sections were stained for general morphology 
observations with hematoxylin and eosin (H&E). Mineral content of the tissue 
was determined via alizarin red staining (Sigma), and collagen alignment with 
picro-sirius red stain. 
 
5.10.3 PCR Analysis – Y Chromosome 
Genomic DNA was isolated from respective bone and ligament regions of the 
BLB tissue samples by proteinase K digestion followed by ethanol precipitation. 
A PCR-based assay for the ovine-specific Y-chromosome repeat sequence 
Ucd043 was used to determine the presence of male cells in BLB explant 
samples 73. Duplex PCR was performed using SCUcd043.FWD/SCUcd043. REV 
primers to amplify Ucd043 together with P1- 5EZ/P2-3EZ primers to amplify the 
ZFY/ZFX locus. P1-5EZ and P2-3EZ primers also provided an internal control for 
amplification. Sensitivity of the assay was assessed with a dilution panel of 100, 
25, and 5 pg of male ovine DNA. Subsequent experimental reactions were 
carried out with 25 ng of genomic DNA template. 
 
5.11 Results 
5.11.1 Flip-Plate Construct Formation 
The ability of the Flip-Plate bioreactor to successfully produce a BLB construct 
without user-dependent manipulation has been demonstrated using the 
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bioreactor and processes detailed above. Briefly, MSCs induced towards an 
osteogenic lineage were sterilely delivered into individual wells within module 1 of 
the device and fed nutrients and growth factors specific to bone formation. A 
bone monolayer is formed, and as it self-delaminated, a constraint system guided 
its formation into two 3D cylindrical bone constructs (Figure 5.10A).  
 
Figure 5.10 Translation of Bone Constructs in Flip-Plate Bioreactor A) Capturing of bone 
constructs, B) Inversion of device, C) Translation of constructs followed by subsequent, 
and D) seeding of ligament cells. As a reference, dimensions of bioreactor device are 7 x 6 
x 2 inches. 
 
Following formation of bone constructs in module 1, the bioreactor cartridge was 
inverted, and the bone constructs were translated via magnets along guides to 
the adjacent unseeded culture surface (Figure 5.10 B, C). Additional MSCs 
induced towards ligamentous lineage were added to the culture surface (Figure 
5.10D), fed nutrients and fibrogenic growth factors, and grown to confluence, 
A B 
C D 
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forming a ligament monolayer. At confluence, the ligament monolayer 
delaminated from the substrate, surrounded the bone constructs (Figure 5.11A), 
and formed a bone-ligament-bone construct that could be removed from the 
bioreactor and utilized as an ACL graft (Figure 5.11 B, C). 
 
 
Figure 5.11 Formation of BLB construct within Bioreactor. A) Delamination of ligament, B) 
Captured BLB construct shown with device opened, and C) BLB construct after removal 
from bioreactor and placed into separate dish. As a reference, construct length is 6 cm for 
each image. 
 
5.12 Construct Validation 
5.12.1 Mechanics 
The ligament region of bioreactor BLB constructs and ligament only controls 
were mechanically tested until failure at one week following formation.  Stress vs. 
strain data are shown in Figure 5.12. Ligament constructs, formed with the manual 
process of Aim 2, had a modulus of 0.38±0.12 MPa (n=3) at a physiological 
strain range of 0.05-0.07. Bioreactor constructs were similar, with an average 
tissue modulus of 0.32±0.11 MPa (n=3). The mechanics of the bone regions 
were not evaluated. The relative standard deviation within each group was 
similar to that reported in Chapter 3, approximately 30%. The diameter of the 
bioreactor constructs were 1.4±0.6 mm for BLBs (n=3) and 0.91±0.03 mm for 
ligament only constructs captured on pin-plates (n=3). 
 
A B C 
 117 
 
Figure 5.12 Failure Stress-Strain Data of Manual vs. Bioreactor Formed Constructs. Strains 
are until failure of ligament region of the BLB construct. 
 
5.12.2 Histology 
Alizarin red staining shows mineral nodules within the bone regions of the graft 
that were absent from the ligament region. This was evidence of a bi-modal 
tissue distribution within the BLB graft (Figure 5.13 A-C). Mineralization was 
comparable to bone and ligament constructs cultured seperately in osteogenic 
and fibrogenic media, respectively, demonstrating a capacity of the tissue to 
maintain a differentiated state while in co-culture. The construct was composed 
of primarily type 1 collagen and contained viable nuclei thoughout (Figure 5.13 D-
F). 
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Figure 5.13 Histological Staining of Bioreactor fabrication BLB Constructs A) Alizarin 
staining of bone region (X4), B) Alizarin staining of bone region (X20), C) Alizarin staining 
of ligament region, D) Col-1/DAPI of bone region (X4), E) Col-1/DAPI of bone region (X20), 
and F) Col-1/DAPI of ligament region. 
 
5.12.3 PCR 
The PCR analysis demonstrates that co-culture of multiple tissues within a 
continuous tissue construct was successful. Male Y chromosome was detected 
in only the bone regions of the construct (Figure 5.14). Female tissue was 
detected throughout the construct and most highly expressed in the central 
ligament region (n=2). Both bone and ligament regions contained significant 
amounts of DNA. 
 
Figure 5.14 PCR Data of Bioreactor Formed BLB Constructs. Bone regions were positive 
for male cell DNA while ligament regions comprised of female cells were not.  
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5.13 Discussion 
5.13.1 Design Elements 
The Flip-Plate bioreactor design successfully meets all previously described 
design criteria. 
 
Minimize Contamination Risk 
The Flip-Plate is designed to be a fully closed system. Although not utilized for 
the initial proof-of-concept prototype, inclusion of sterile inline attachments for 
media exchange to the inlet and outlet fittings of the bioreactor device can 
completely seal the device from the external environment.  Being a closed 
system, perfusion is required for the infusion of temperature and gas controlled 
media. The use of a perfusion system allows for precise control of culture 
parameters and the potential for continuous system monitoring and in-line media 
sampling. Such a system can greatly improve the safety of the device and 
comply with current CGMP standards.  
 
However, the inclusion of a perfusion system introduces additional variables into 
the system that can alter cell adherence and growth. It also adds an increased 
level of complexity to the device requiring additional costs and labor time to 
implement. For these reasons, the fittings of the bioreactor were left open, 
exposed to the local environmental condition, creating a semi-closed system. 
Use of the bioreactor as a semi-closed system still significantly limited external 
exposure to contamination. This permitted the bioreactor to fully replicate the pre-
defined BLB fabrication methodologies to allow cell growth within a sterile 
incubator at 37C, 95% humidity, and 5%CO2 and media exchange within a sterile 
laminar flow hood. The semi-closed bioreactor still provides reduced 
contamination risk by eliminating direct user-contact with cells and tissue. Cell 
injection and media exchange are performed only through sterile injection ports 
via the syringe push-pull system. Despite being slightly exposed to the external 
environment, no contamination was observed with use of this device. Once the 
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cells are injected into the device, the two culture surfaces are not taken apart 
until the final tissue graft has been created and matured. 
 
The entire device is fabricated from FDA compliant materials. Aside from the 
disposable cell culture surfaces, the entire system can be sterilized by traditional 
sterilization techniques (autoclaving or ethylene oxide) and reused. Further UV 
treating of the device following assembly in a laminar flow hood further ensures 
the sterility of the device prior to use. When fully closed, the device can be used 
as a container for tissue preservation, storage, and shipping. The overall goal is 
to deliver the preserved graft within the device so that it can be stored and 
opened when needed by the surgeon. 
 
Eliminate Manual, User-Depended Processes 
Eventually, the bioreactor system will be designed for complete automation. As 
opposed to our current manual, user-dependent technology utilized in previous 
BLB fabrication methods, all physical manipulations were performed on the 
exterior of the device. This eliminated the user-variability associated with forming 
the 3D BLB graft during the tissue combination process. Smooth and efficient 
translation of the tissue was achieved by utilizing a magnet to pull the sutures. 
Though other modes of movement are feasible, the utilization of a magnetic field 
to provide translation allows the translational mechanism to be completely sealed 
from the external environment. The end result is a much more consistent 
manufacturing process not reliant on technician skill.  
 
The eventual attachment of the bioreactor cartridge into a larger mechanical 
system will allow for automated magnetic manipulation and inversion, or flipping, 
of the device. If used in combination with an automatic perfusion system, larger 
quantities of grafts can be fabricated with minimal need for a technician.  
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Economically Scalable 
The lack of reliance upon technician skill or labor through design of an automated 
system would greatly improve the economic viability of the device with scale. The 
bioreactor is modular, meaning several bioreactor cartridge systems can be 
connected in parallel to a single media reservoir and manifold system. This 
allows for the production of multiple grafts with little additional costs. The Flip-
Plate device was also designed to have a relatively small footprint to maximize 
space and reduce infrastructure costs with large-scale manufacturing. The 
current dimensions were chosen due to ease of manufacturing. Small profile 
devices can be achieved through more skillful machining processes such as 
injection molding. 
 
5.13.2 Performance Requirements 
The Flip-Plate bioreactor successfully produced a construct that was 
morphologically similar to previous work 105, thus demonstrating the successful 
adaptation of our manual BLB fabrication methods into a semi-closed automated 
process. The entire construct was continuous with compositionally different 
tissue at each end. Mineralized matrix was observed in the bone regions of the 
graft despite the removal of dexamethasone and prolonged exposure to ligament 
growth medium. Mechanically, despite being similar to the ligament-only controls, 
the modulus of the ligament region of the graft was approximately an order of 
magnitude lower than previously data described in section 3.5.5. The reason for 
this is likely due to the difference in maturation time of only 1 week in the present 
study. Further studies will investigate whether additional time in vitro may 
improve matrix remodeling and graft mechanics at later time points.  
 
Size disparity was also observed between experiments. Larger 5 mm and 2 mm 
diameter constructs formed during stage 1 at one-week time points in 100 mm 
and 150 mm plates, respectively, were not reproduced during Flip-Plate 
bioreactor experiments. Flip-Plate BLB constructs were approximately 2-3 mm in 
diameter. Inherent variability in cell ECM synthesis and remodeling likely account 
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for these differences. Previous work has demonstrated the ability of the BLB 
construct to significantly grow in size in vivo approximating the native tissue 
dimensions. Despite this feature, the in vitro construct must still maintain a 
consistent and robust diameter to provide sufficient structural integrity during the 
implantation procedure. Therefore, strategies to maintain construct size, such as 
alteration of culture surface area, the removal of TGF-B, or release of suture 
tension, may be needed to prevent excessive tissue condensation and better 
preserve construct diameter and viability. 
 
Delamination and 3D tissue formation within the Flip-Plate bioreactor was 
facilitated through the use of tensioned sutures, rather than conventional pin-
plates described previously. During both trans-osseous rotator cuff repair and 
anatomic ACL reconstructive surgery, the tissue-engineered graft is sutured to 
the periosteum of the bone. The inclusion of the suture during the fabrication 
process provides adequate material to secure the ends of the graft and anchor 
the construct during surgery. Inclusion of alternative suture configurations may 
enhance suture-graft integration and provide additional stability during 
implantation and fixation to native tissue. Additionally, through automated 
manipulation of suture tension, mechanical conditioning of the graft could be 
performed to modulate the maturation and physical properties of the tissue graft. 
 
5.14 Conclusion 
In conclusion, the work outlined in this aim demonstrates the feasibility of 
converting traditional bench-scale tissue culture techniques into a closed, 
automated bioreactor system. In addition, this work describes and validates a 
novel bioreactor design for the fabrication of scaffold-free, multi-phasic, co-
cultured tissue grafts for musculoskeletal repair. The application of bioreactors 
for the generation of tissue-engineered products can lower contamination risks 
and reduce user-dependency, providing a more consistent and economically 
scalable manufacturing process. The development of cost-effective, scalable, 
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and regulatory compliant manufacturing procedures early in the research stages 
of product development and before pre-clinical and clinical trials can significantly 
lower the technical, regulatory, and financial hurdles limiting the current 
translation of products within the tissue engineering field. 
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Chapter 6  
Thesis Conclusions and Future Work 
6.1 Conclusions 
The objectives of this thesis were to evaluate the efficacy of our scaffold-less 
tissue engineered constructs to regenerate the rotator cuff enthesis following 
repair and to advance our existing construct fabrication methodologies to more 
standardized and commercially relevant manufacturing processes. To 
accomplish these objectives, the research of this thesis was guided by three 
aims. Aim 1 focused on the repair of full thickness rotator cuff tears following 
acute and chronic injury, utilizing our scaffold-less 3D construct methodologies. 
As described in Chapter 2, use of our engineered tissues improved the 
regeneration of the rotator cuff enthesis compared to existing suture repair 
techniques. The re-establishment of the native enthesis is critical for modulating 
loads at the tendon/bone interface and its regeneration may lead to the 
improvement of repair outcomes following rotator cuff repair.  
 
Aim 2 focused on the standardization of construct fabrication methodologies for 
uniform, reproducible, and clinically relevant tissue production. As described in 
Chapter 3, the use of a non-terminal bone marrow aspiration technique, a Ficoll 
cell isolation method, a defined passaging density, and a novel monolayer 
capturing “pin-plate”, greatly improved the consistency and efficiency of our 
manufacturing process. Furthermore, the application of these processes using 
human derived MSCs successfully demonstrated the feasibly of our methods to 
fabricate ligament and bone tissues from a clinically relevant cell source without 
the use of exogenous scaffolding (Chapter 4). The addition of these 
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manufacturing processes is a significant step towards the translation of these 
scaffold-less technologies for human use and enables a more efficient process 
for construct production.   
 
However, to further expedite the commercialization of this technology and to 
comply with existing FDA manufacturing guidelines, a novel bioreactor system 
was designed, built, and evaluated as described in Aim 3. Because no existing 
bioreactor systems existed for the closed, automated manufacturing of multiple 
tissues within a single chamber, a new Flip-Plate bioreactor device was 
developed (Chapter 5). The successful fabrication of a BLB construct within a 
semi-closed chamber, without the need for direct tissue manipulation by a 
technician, allows for scalable tissue production needed for large scale BLB graft 
manufacturing. By addressing issues related to the development and 
manufacturing of tissue engineering technologies early in the manufacturing 
process, our ability to overcome current challenges that limit the development of 
new medical products in the field of regenerative medicine is enhanced. 
 
6.2 Future Work 
Future work related to this thesis will focus on the continued evaluation of our 
constructs in a rotator cuff repair model. Specifically, the safety and efficacy of 
the constructs following implantation must be evaluated as required by the FDA. 
While the results of Aim 1 were encouraging in a rat rotator cuff repair model, the 
construct’s utility in a large animal model will need to be demonstrated. 
Additionally, the toxicological response and in vivo function of the graft must be 
investigated before proceeding into clinical trials. 
 
The manufacturing process of our scaffold-less constructs must also be further 
validated. While the described methodologies are a significant improvement over 
existing protocols, they lack the sample size and validation needed to effectively 
demonstrate the safety and reproducibly of the manufacturing process to the 
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FDA. Moreover, having optimized production of only the ligament region of our 
BLB graft, future work is needed to optimize methods related to the formation of 
scaffold-less bone tissues. To facilitate commercial manufacturing of BLB 
constructs, several fully automated Flip-Plate bioreactors must be built in order to 
simultaneously produce a large number of constructs at an economical cost. 
Production of these constructs will be vital for characterizing the attributes of our 
tissues and establishing product specifications for our BLB grafts. They will also 
be needed to support future large-scale FDA process validation studies and the 
widespread clinical use of our product.  The research of this thesis presents a 
new enthesis repair strategy to improve the treatment of musculoskeletal injuries 
involving the ACL and rotator cuff tendons. By overcoming the current 
translational challenges related to product development and industrialized 
manufacturing early in the research process, the work of this thesis will hopefully 
provide a framework for expediting the clinical and commercial translation of 
other tissue engineering products in the field. 
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